JP6882383B2 - インスリン管理 - Google Patents
インスリン管理 Download PDFInfo
- Publication number
- JP6882383B2 JP6882383B2 JP2019126913A JP2019126913A JP6882383B2 JP 6882383 B2 JP6882383 B2 JP 6882383B2 JP 2019126913 A JP2019126913 A JP 2019126913A JP 2019126913 A JP2019126913 A JP 2019126913A JP 6882383 B2 JP6882383 B2 JP 6882383B2
- Authority
- JP
- Japan
- Prior art keywords
- blood glucose
- insulin
- time interval
- computer device
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 543
- 102000004877 Insulin Human genes 0.000 title claims description 272
- 108090001061 Insulin Proteins 0.000 title claims description 272
- 229940125396 insulin Drugs 0.000 title claims description 272
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 457
- 239000008103 glucose Substances 0.000 claims description 457
- 239000008280 blood Substances 0.000 claims description 455
- 210000004369 blood Anatomy 0.000 claims description 455
- 238000000034 method Methods 0.000 claims description 259
- 238000005259 measurement Methods 0.000 claims description 167
- 230000008569 process Effects 0.000 claims description 158
- 235000012054 meals Nutrition 0.000 claims description 147
- 235000005911 diet Nutrition 0.000 claims description 103
- 230000000378 dietary effect Effects 0.000 claims description 86
- 238000001990 intravenous administration Methods 0.000 claims description 75
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 65
- 238000001802 infusion Methods 0.000 claims description 43
- 150000001720 carbohydrates Chemical class 0.000 claims description 40
- 235000014633 carbohydrates Nutrition 0.000 claims description 40
- 208000013016 Hypoglycemia Diseases 0.000 claims description 29
- 238000007920 subcutaneous administration Methods 0.000 claims description 28
- 230000007704 transition Effects 0.000 claims description 27
- 230000015654 memory Effects 0.000 claims description 18
- 230000037213 diet Effects 0.000 claims description 17
- 230000036961 partial effect Effects 0.000 claims description 14
- 230000006870 function Effects 0.000 claims description 11
- 238000004904 shortening Methods 0.000 claims description 11
- 238000011421 subcutaneous treatment Methods 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000006641 stabilisation Effects 0.000 claims description 3
- 238000011105 stabilization Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 description 62
- 238000004364 calculation method Methods 0.000 description 60
- 230000002641 glycemic effect Effects 0.000 description 17
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000004590 computer program Methods 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 230000008859 change Effects 0.000 description 11
- 238000004891 communication Methods 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 201000001421 hyperglycemia Diseases 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 208000028399 Critical Illness Diseases 0.000 description 3
- 240000007839 Kleinhovia hospita Species 0.000 description 3
- 102000016261 Long-Acting Insulin Human genes 0.000 description 3
- 108010092217 Long-Acting Insulin Proteins 0.000 description 3
- 229940100066 Long-acting insulin Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- ZLLVUAAESHIVAZ-UHFFFAOYSA-N benzo[g]isoquinoline-5,10-dione Chemical compound N1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 ZLLVUAAESHIVAZ-UHFFFAOYSA-N 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000010030 glucose lowering effect Effects 0.000 description 2
- 229940127560 insulin pen Drugs 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000021476 total parenteral nutrition Nutrition 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14288—Infusion or injection simulation
- A61M2005/14296—Pharmacokinetic models
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/18—General characteristics of the apparatus with alarm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3561—Range local, e.g. within room or hospital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
Description
食事インスリンボーラス={食事における炭水化物のグラム数}/ CIR (1)
CB = (BG - BGTarget) / CF (2)
{
$this->load->helper(’formula’);
$PatientID = $this->input->post("PatientID");
$CurrentBG = $this->input->post("iv_bg_input");
$Premeal = $this->input->post("pre_meal");
$EstCarbs = $this->input->post("carbs");
$CancelPreMeal = $this->input->post("CancelPreMeal");
$PatientEat = $this->input->post("patient_eat");
$ActualCarbs = 0;
$MealBolus = $this->input->post("MealBolus");
$MealBolusCount = 0;
$LastBGData = $this->iv->GetLastIVBG($PatientID);
$PreviousBG = $LastBGData->BGValue;
$PreviousBGRate = $LastBGData->InsulinRate;
$iir_results = $this->CalculateIIR($PatientID, $CurrentBG, $LastBGData, $EstCarbs);
$MealBolusDose = 0;
$iir = $iir_results["iir"];
$multiplier = $iir_results["multiplier"];
$ActualCarbs = 0;
$PostPlateCheck = false;
$MinutesInTransition = $this->iv->GetTransitionMinutesInTransition($PatientID);
$StartingMultiplier = $LastBGData->SensitivityFactor;
if($LastBGData->EstNumberOfCarbs == 12 && $LastBGData->ActualNumberOfCarbs == 15)
{$LastBGCarbsGiven = true;}
else
{$LastBGCarbsGiven = false;}
if($PatientEat == 0 && $EstCarbs>0 && $Premeal!= 1)
{
$MealBolusData = $this->iv->GetCurrentMealBolusInfo($PatientID);
if($MealBolusData ["NumCount"]<2)
{
$CancelPreMeal = "yes";
}
}
if($Premeal == "1")
{
$MealBolus = 1;
$ActualCarbs = 0;
$MealBolusCount = 0;
}
else if($MealBolus == 1)
{
$MealBolus = 1;
$EstCarbs = $LastBGData->EstNumberOfCarbs;
$meal_eat = $this->input->post("meal_eat");
if($meal_eat=="input")
{$ActualCarbs = $this->input->post("meal_eat_input_val");}
else
{$ActualCarbs = $meal_eat/100*$EstCarbs;}
$TimeInterval = $LastBGData->TimeInterval ;
$MealBolusCount = 1;
if($ActualCarbs ==0)
{$MealBolus = 0;}
}
else
{
$MealBolusData = $this->iv->GetCurrentMealBolusInfo($PatientID);
if ($MealBolusData["NumCount"] > 0 && $MealBolusData["NumCount"]<=2)
{
$MealBolus = 1;
$EstCarbs = $MealBolusData["EstNumberofCarbs"];
$ActualCarbs = $MealBolusData["ActualNumberofCarbs"];
$MealBolusCount = $MealBolusData["NumCount"];
if($MealBolusData["NumCount"] <2)
{
$TimeInterval = $this->iv->getPostPlateCheckInterval($PatientID);
$PostPlateCheck = true;
}
else
{
$TimeInterval = $MealBolusData["TimeInterval"] ;
}
}
}
if($CancelPreMeal=="yes")
{$MealBolus =0;}
if($MealBolus ==1)
{
if($Premeal != "1")
{
$multiplier = $LastBGData->SensitivityFactor;
}
$MB = $this->CalculateMealBolusIIR($PatientID, $CurrentBG, $EstCarbs, $ActualCarbs, $LastBGData, $multiplier, $MealBolusCount, $TimeInterval );
if ($PostPlateCheck)
{$ActualCarbs = 0;}
$iir = round($MB[0],1);
$MealBolusDose = round($MB[2],2);
if($MealBolusDose == 0.00)
{$MealBolusDose = 0.01;}
}
$iir_display = $iir;
if($this->default->InsulinUnitOfMeasure != ’units/hr’)
{
$iir_display = $iir_display/$LastBGData->InsulinConcentration;
$iir = $iir/$LastBGData->InsulinConcentration;
}
// settings
$hospital_settings = $this->patient->GetHospitalUnitInfoByHospitalUnitID($LastBGData->HospitalUnitID);
//get the value from configurable option
$HypoTreatmentValue= is_numeric($hospital_settings->HypoTreatment)−$hospital_settings->HypoTreatment:60;
$StopInsulinBGValue = $this->systemsettings->GlobalSetting("StopInsulinBGValue");
if(
(trim(strtolower($StopInsulinBGValue)) == "targetlow") || empty($StopInsulinBGValue) || !isset($StopInsulinBGValue) ||
($StopInsulinBGValue > $LastBGData->TargetLow)
)
{$StopInsulinBGValue = $LastBGData->TargetLow;}
//if IIR gets this high, stop!!!
$StopInsulinRecommendation =
getOneField("StopInsulinRecValue","xStopInsulinRecommendation","StopInsulinRecID", $hospital_settings->StopInsulinRecomm);
$default_iir_limit = $this->options->ListData("Warning_IRGreaterThanValue","xWarning_IRGreaterThan","Warning_IRGreaterThanID = ’" . $hospital_settings->DisplayWarn . "’",true)->Warning_IRGreaterThanValue;
$ShowHighRateWarning = ($iir >= $default_iir_limit);
$HighRateLimit = $default_iir_limit;
$showInsulinResistance = false;
$showD50 = false;
$showHTF = false;
$stopInsulin = false;
$D50 = 0;
if($CurrentBG >= 250)
{
$showInsulinResistance = $this->iv->CheckIfInsulinResistance($PatientID);
}
if ( ($CurrentBG <= $HypoTreatmentValue) && ($CurrentBG < $LastBGData->TargetLow) )
{
$D50 = (100-$CurrentBG)*0.4;
$D50 = round($D50, 0);
//IIR for D50 is always 0
$iir = 0;
$iir_display = 0;
if ($CurrentBG <= $HypoTreatmentValue)
{
$showD50 = true;
}
else
{
if ($CurrentBG > 60)
{
$showHTF = true;
}
}
}
$stopInsulin = ($showD50 || ( $CurrentBG<=$StopInsulinBGValue && $CurrentBG < $LastBGData->TargetLow));
$showIIR = (!($showD50 || $showHTF ));
$showD50Dupe = false;
if($showD50 && $LastBGData->BGID > 0)
{
if(
($LastBGData->MinutesFromLastBG<20) &&
($LastBGData->BGValue < $CurrentBG)
)
{
$showD50 = false;
$showD50Dupe = true;
$iir = 0;
$D50 = 0;
}
}
if($stopInsulin)
{$iir = "0";}
$UseGTFluid = $this->UseGTFluid ($PatientID, $CurrentBG);
$BGData = array(
"ActualCarbs"=>$ActualCarbs,
"EnableFluidManage" => $hospital_settings->EnableFluidManage,
’FluidType’ => ($UseGTFluid)−$LastBGData->Over250Fluid:$LastBGData->Under250Fluid,
’FluidRate’ => ($UseGTFluid)−$LastBGData->Over250Rate:$LastBGData->Under250Rate,
’BGValue’ => $CurrentBG,
’InsulinRate’ => $iir,
’SensitivityFactor’ => $multiplier,
’D50W’ => $D50,
’PatientEat’=>$PatientEat,
’MealBolusDose’ => $MealBolusDose,
"CreateDate" => getOneField("dbo.fnGluDateTime()", "Patients", "PatientID", $PatientID)
);
if($stopInsulin)
{
$iir = 0;$iir_display = 0;
}
$ShowWarningContactPhysician= ($iir >= $StopInsulinRecommendation && $StopInsulinRecommendation!= "");
if($ShowWarningContactPhysician)
{
$ShowHighRateWarning =false;
$iir = $StopInsulinRecommendation;
$iir_display = $StopInsulinRecommendation;
$BGData["InsulinRate"] = $StopInsulinRecommendation;
$BGData["SensitivityFactor"] = $StartingMultiplier;
}
$SameIIR = false;
if($PreviousBGRate == $iir_display){
$SameIIR = true;
}
$data= array(
"iir" => $iir,
"iir_display"=>$iir_display,
"InsulinUnitOfMeasure" => $this->default->InsulinUnitOfMeasure,
"showInsulinResistance" => $showInsulinResistance, "showD50"=>$showD50,
"showD50Dupe"=>$showD50Dupe,
"showHTF"=>$showHTF,
"showIIR"=>$showIIR,
"stopInsulin"=>$stopInsulin,
"D50"=>$D50,
"HypoTreatmentValue"=>$HypoTreatmentValue,
’PrevD50W’ => $LastBGData->D50W,
"LastBGData" => $LastBGData,
"default" => $this->default,
"SecondNurseVerification" => $hospital_settings->EnableSecondNurseVer,
"ShowHighRateWarning" => $ShowHighRateWarning,
"HighRateLimit" => $HighRateLimit,
"ShowWarningContactPhysician" => $ShowWarningContactPhysician,
’BGData’=>$BGData,
’SameIIR’=>$SameIIR,
’PatientEat’=>$PatientEat,
"IsDistinueIV" =>$MinutesInTransition>=240−true:false,
’EnableHypoglycemiaMessage’=>$hospital_settings->EnableHypoglycemiaMessage,
’MinutesFromLastBG’ => $LastBGData->MinutesFromLastBG,
’HypoglycemiaMessage’=>$hospital_settings->HypoglycemiaMessage,
’LastBGCarbsGiven’ =>$LastBGCarbsGiven,
’IVDiscontinueRecomm’ => $this->iv->IVDiscontinueRecomm($PatientID, $iir),
’AreLastFourInsulinRatesLow’ => $this->iv->AreLastFourInsulinRatesLow($PatientID, $iir)
);
//Loading History Data
$UserID = $this->session->userdata[’logged_in’][’UserID’];
if(($data["showIIR"]))
{
$DosageAmount = $data["iir_display"];
$DosageLabel = dealWithInsulinMeasurement($data["InsulinUnitOfMeasure"],$data["iir_display"]);
}
if($data["showD50"])
{
if($EnableHypoglycemiaMessage == 1) {
$DosageAmount = "null";
$DosageLabel = "Stop Insulin Infusion";
}
else
{
$DosageAmount = $D50;
$DosageLabel = "D50 or 12-15 Grams of Carbs";
}
}
//if $DosageAmount is empty and $DosageLabel is empty
if(empty($DosageAmount) && empty($DosageLabel)){
$DosageAmount = 0;
$DosageLabel = null;
}
$this->load->model("patient");
$this->patient->AddDosageRecommendationHistory($PatientID, 1,1, $CurrentBG, $DosageAmount, $DosageLabel, $UserID);
$this->load->view("forms/bg/iv_bg_checkboxes", $data);
}
function UseGTFluid($PatientID, $CurrentBG)
{
//BR5.2
if($CurrentBG >= 300)
{return true;}
//BR5.1
$Last3BGs = $this->iv->Last2BGs($PatientID);
if(count($Last3BGs) == 0 && $CurrentBG >= 250)
{return true;}
//BR5.3
if($CurrentBG>=250 && $Last3BGs[0]->OverUnder == "over")
{return true;}
//BR5.4
if($CurrentBG>=250 && $Last3BGs[0]->BGValue >=250 && $Last3BGs[1]->BGValue >=250)
{return true;}
//default BR5.5
return false;
}
function CalculateMealBolusIIR($PatientID, $CurrentBG, $EstimatedCarbs, $ActualCarbs, $LastBGData, $Multiplier, $MealBolusCount, $TimeInterval)
{
$InsulinUnitsOfMeasure = GetOneField("SettingValue", "GlobalSettings", "SettingName", "InsulinUnitOfMeasure");
$r = PreMealIIR(
$PatientID,
$CurrentBG,
$Multiplier,
$LastBGData->InsulinConcentration,
$EstimatedCarbs, $ActualCarbs,
$TimeInterval,
$InsulinUnitsOfMeasure,
$MealBolusCount
);
$r[0] = round($r[0], 5);
return $r;
}
function CalculateIIR($PatientID, $CurrentBG, $LastBGData, $EstCarbs)
{
/*Adjust Multiplier*/
$multiplier = $LastBGData->SensitivityFactor;
/*add the conditon $LastBGData->SensitivityFactor == $LastBGData->PreBGSensitivityFactor
if change the Multiplier by manually ,it should not be changed.
updated by stanley on 10/30/2013
*/
if(($LastBGData->BGID!=0 || $EstCarbs > 0) && ($LastBGData->SensitivityFactor == $LastBGData->PreBGSensitivityFactor) )
{
if(
($CurrentBG > $LastBGData->TargetHigh) &&
(($CurrentBG / $LastBGData->BGValue) > 0.85)
)
{
$multiplier = $multiplier* 1.25;
}
elseif($CurrentBG < $LastBGData->TargetLow)
{
$multiplier = $multiplier * 0.8;
}
}
$multiplier = round($multiplier, 5);
//Calc IIR
$IIR = round( ($CurrentBG - 60) * $multiplier, 1);
if($IIR < 0)
{$IIR = 0;}
$return = array(
"iir"=>$IIR,
"multiplier" => $multiplier,
);
return $return;
}
ここで、Kはオフセットターゲットとして公知の定数であり、血糖と同じ単位の尺度を有し、Mは単位なし乗数である。一部の例では、オフセットターゲットKは、患者10の血糖ターゲット範囲よりも低い。オフセットターゲットKは、投薬量計算処理300が血糖ターゲット範囲BGTRにある血糖結果を有する非ゼロ安定インスリン投薬速度を計算することを可能にする。
MI = 0.0002 x患者の体重 (キログラムで) (3B)
一部の実施では、Kは60mg/dlに等しい。投薬量計算処理300は、ユーザ40によって入力された2つの限界、すなわち、ターゲット範囲の下限BGTRL及びターゲット範囲の上限(高)値BGTRHを使用して、ターゲット血糖ターゲット範囲BGTRを決定する。これらの限界は、中間点として望ましい血糖ターゲットを含有するようにユーザ40によって選択される。これに加えて、オフセットターゲットKは、次式に従って動的に計算することができる。
K = BGTarget−オフセット (4)
ここで、BGTargetは血糖ターゲット範囲BGTRの中間点であり、オフセットは、ターゲット中心BGTargetとオフセットターゲットKの間の事前に構成された距離である。
function IIR($sf, $current_bg, $bg_default = 60, $insulin_concentration, $ins_units_of_measure = ’units/hr’) {
settype($sf,’float’);
settype($bg_default,’float’);
settype($current_bg,’float’);
settype($insulin_concentration,’float’);
/*
@param $sf = sensitivity factor from db
@param $current_bg = the current bg value being submitted
@param $db_default = the default "Stop Insulin When" value....If it isn’t passed, it defaults to 60
@param $insulin_concentration = the default insulin concentration from settings
*/
if($current_bg > 60) {
$iir = array();
$iir[0] = round(($current_bg - $bg_default) * $sf, 1);
if ($ins_units_of_measure != ’units/hr’) {
$iir[1] = round(($current_bg - $bg_default) * $sf / $insulin_concentration ,1);
}
return $iir;
} else {
return 0;
}
}
(BG / BGP) > LA (5)
ここで、BGは、患者の現在の血糖値であり、BGpは、患者の以前の血糖値であり、LAは、血糖ターゲット範囲の上限BGTRHよりも上の血糖値のBG/BGpの閾値比である。比BG/BGpが閾値比LAを超える場合に、乗数Mが増加する。一部の例では、閾値比LAは0.85に等しい。
M = MP (6)
M = MP / MCF (7)
に従って現在の乗数Mの値を乗数変化係数(MCF)で除算して、ブロック320で式3を使用して現在のインスリン注入速度IIRを計算して処理200(図2を参照)に戻る。
以下:
であるので、
ここで、BGpは、以前に測定された血糖である。
を使用して、血糖BGが限界%DropRegular(通常範囲、すなわち、血糖値BG>BGTRLに対する)を超える以前の血糖のパーセントだけ減少したか否かをブロック420で決定する。
BGDropRate = (BGP - BG) / (TCurrent - TPrevious) (10)
に基づいて血糖の下降速度BGDropRateを決定し、ここで、BGpは以前の血糖測定値であり、TCurrentは現在の時間及びTPreviousは以前の時間である。更に、処理400は、血糖の下降速度BGDroprateが事前に構成された降下速度限界BGdropRateLimitよりも高いか否かをブロック412で決定する。
推定食事ボーラス= EstimatedCarbs / CIR (11A)
ここで、CIRは、上述の炭水化物対インスリン比である。
推定食事ボーラス速度=推定食事ボーラス* C / TMealBolus1 (11B)
ここで、TMealBolus1は、食事ボーラス合計期間TMealBolusの第1時間間隔の持続時間である。Cは、第1時間間隔TMealBolus1中に推定食事ボーラスの最適部分を注入するように調節された定数である。例えば、推定食事ボーラス=6単位、TMealBolus1=0.5時間、及びC=25%である場合に、例として式11Aを適用する。
推定食事ボーラス速度=(6単位)*25% / (0.5時間)=3単位/時間 (11C)
食事ボーラス処理500は、次式のようにブロック508で合計インスリン速度を計算する。
合計インスリン注入速度=推定食事ボーラス速度+ 通常静脈内速度 (12)
修正食事ボーラス= ActualCarbs / CIR (13A)
供出された推定食事ボーラス=推定食事ボーラス速度* (T2 - T1) (13B)
ここで時間T1は、第1血糖値BG1が測定される時間であり、時間T2は、第2の血糖値BG2が測定される時間である。
残りの修正食事ボーラス=推定食事ボーラス−供出された推定食事ボーラス (13C)
修正食事ボーラス速度=残りの修正食事ボーラス/残りの時間 (14A)
ここで残りの時間=TMealBolus−TMealBolus1である。合計時間間隔TMealBolus及び第1時間間隔TMealBolus1が事前に構成された値であるので、残りの時間を決定することができる。
合計インスリン速度=修正食事ボーラス速度+ IIR (14B)
function PreMealIIR($PatientID, $CurrentBG, $Multiplier, $InsulinConcentration, $EstCarbs, $ActualCarbs, $TimeInterval, $InsulinUnitsOfMeasure, $MealBolusCount) {
$iir = array();
$CarbInsulinRatio = CIR($PatientID);
$NormalInsulin = ($CurrentBG - 60) * $Multiplier;
if($MealBolusCount == 0)
{
//first run - Premeal Bolus
$MealBolus = ($EstCarbs /$CarbInsulinRatio);
if($MealBolus <0)
{$MealBolus = 0;}
$iir[0] = $NormalInsulin + ( $MealBolus *.5 );
$iir[2] = ( $MealBolus *.5 );
/*
print "Premeal: MX: " . $Multiplier . "<BR>";
print ($CurrentBG - 60) * $Multiplier;
print " + " ;
print ( $MealBolus *.5 );
*/
} else if($MealBolusCount == 1){
//second run Post Meal Bolus
//third run time interval coming in is actually the
//difference between the premeal BG and the first Post Meal BG (second run)
$MealBolus = ($ActualCarbs / $CarbInsulinRatio);
$OldMealBolus = ($EstCarbs / $CarbInsulinRatio);
$CurrentMealBolus = ($MealBolus - ($OldMealBolus *.5 * $TimeInterval))/1.5;
if($CurrentMealBolus <0)
{$CurrentMealBolus =0;}
$iir[0] = $NormalInsulin + $CurrentMealBolus ;
$iir[2] = $CurrentMealBolus ;
/*
print "PlateCheck: <BR>MX: " . $Multiplier . "<BR>";
print "Est Carbs: " . $EstCarbs . "<BR>";
print "ActualCarbs: " . $ActualCarbs . "<BR>";;
print "CarbInsulinRatio: " . $CarbInsulinRatio . "<BR>";
print "TimeInterval: " . $TimeInterval . "<BR>";
print "Multiplier: " . $Multiplier;
*/
}
else
{
$MealBolus = ($ActualCarbs / $CarbInsulinRatio);
$OldMealBolus = ($EstCarbs / $CarbInsulinRatio);
/*
print "Actual Carbs: " . $ActualCarbs . "<BR>";
print "Est Carbs: " . $EstCarbs . "<BR>";
print "CIR: " . $CarbInsulinRatio . "<BR>";
print "Multiplier: " . $Multiplier . "<BR>";
print "CurrentBG: " . $CurrentBG . "<BR>";
print "IIR: " . (($CurrentBG - 60) * $Multiplier) . "<BR>";
print "MealBolus: " . $MealBolus . "<BR>";
print "OldMealBolus: " . $OldMealBolus . "<BR>";
print "TimeInterval: " . $TimeInterval . "<BR>";
*/
$CurrentMealBolus = ($MealBolus - ($OldMealBolus *.5 * $TimeInterval))/1.5;
if($CurrentMealBolus <0)
{$CurrentMealBolus =0;}
$iir[0] = $NormalInsulin + $CurrentMealBolus;
$iir[2] = $CurrentMealBolus;
/*
print "Post PlateCheck: <BR>MX: " . $Multiplier . "<BR>";
print "IIR: ";
print ($CurrentBG - 60) * $Multiplier . "<BR>";
print "Est Carbs: " . $EstCarbs . "<BR>";
print "Acutal Carbs: " . $ActualCarbs . "<BR>";
print "Old Meal bolus: " . $OldMealBolus . "<BR>"; print "TimeInterval: " . $TimeInterval . "<BR>";
print "Meal bolus: " . $MealBolus . "<BR>";
print "Final Calc: " . $iir[0];
*/
}
if ($InsulinUnitsOfMeasure != "units/hr")
{
$iir[0] = $iir[0]/$InsulinConcentration;
}
return $iir;
}
TDD = QuickTransitionConstant * MTrans (15A)
ここで、QuickTransitionConstantは、通常は1000であり、MTransは、SubQ移行処理の開始の時間での患者の乗数である。
TDD = 0.5 * Weight (kg) (15B)
TDD = (BGTarget - K) * (MTrans) * 24 (16)
ここでMTransは、SubQ移行処理の開始の時間での患者の乗数である。
function getIV_TDD($PatientID)
{
//$weight = getOneField("weight", "patients", "patientID", $PatientID);
//return $weight/2;
$CI = get_instance();
$CI->load->model(’options’);
$d = $CI->options->GetIVTDDData($PatientID);
$TargetHigh = $d["TargetHigh"];
$TargetLow = $d["TargetLow"];
$Multiplier = $d["Multiplier"];
$MidPoint = ($TargetHigh + $TargetLow) / 2;
$Formula = ($MidPoint - 60) * $Multiplier * 24;
return $Formula;
}
Claims (15)
- 静脈内インスリン注入速度(IRR)を連続的に計算するためのグルコメータ(124)及びコンピュータデバイス(112、132、142)の作動方法(700)であって、
前記グルコメーター(124)から、時間間隔(TNext)によって分離された現在の血糖測定値と以前の血糖測定値(BGPrevious)とを有する血糖測定値(BG)を前記コンピュータデバイス(112、132、142)上で受信する段階と、
前記受信された血糖測定値(BG)を前記コンピュータデバイス(112、132、142)と通信する非一時的メモリ(144)に記憶する段階と、
各時間間隔(TNext)に対して、
前記コンピュータデバイス(112、132、142)が、前記時間間隔(TNext)の前記血糖測定値(BG)に基づいて静脈内インスリン注入速度(IRR)を決定する段階、
前記コンピュータデバイス(112、132、142)が、前記血糖測定値(BG)に基づいて血糖パーセント降下(BG%Drop)を決定する段階、
前記コンピュータデバイス(112、132、142)が、前記血糖測定値(BG)と前記時間間隔(TNext)とに基づいて血糖降下速度(BGDropRate)を決定する段階、
前記コンピュータデバイス(112、132、142)が、前記血糖パーセント降下(BG%Drop)が閾値パーセント降下(%DropLowLimit)よりも高い時に前記グルコメーター(124)による血糖測定値(BG)間の前記時間間隔(TNext)を短くする段階、及び、
前記コンピュータデバイス(112、132、142)が、前記血糖降下速度(BGDropRate)が閾値降下速度(BGDropRateLimit)よりも高い時に前記グルコメーター(124)による血糖測定値(BG)間の前記時間間隔(TNext)を短くする段階と、
を含むことを特徴とする方法(700)。 - 前記コンピュータデバイス(112、132、142)が、
前記グルコメーター(124)による前記血糖測定値(BG)間の前記時間間隔(TNext)をデフォルト時間間隔(TDefault)に設定するか;あるいは
現在の血糖測定値(BG)が閾値低血糖症血糖値(BGHypo)よりも低い時の、事前に構成された低血糖症時間間隔(THypo):
前記現在の血糖測定値(BG)が前記閾値低血糖症血糖値(BGHypo)よりも高く、かつ、血糖ターゲット範囲(BGTR)の下限(BGTRL)よりも低く、かつ、前記血糖パーセント降下(BG%Drop)が低血糖パーセント降下限界(%DropLowLimit)よりも高いか、又は
前記現在の血糖測定値(BG)が前記血糖ターゲット範囲(BGTR)の下限(BGTRL)よりも高いか又はそれに等しく、かつ、前記血糖パーセント降下(BG%Drop)が通常血糖パーセント降下限界(%DropRegularLimit)よりも高い、
という時の、事前に構成された短い時間間隔(TShort):
前記血糖降下速度(BGDropRate)が血糖降下速度限界(BGDropRateLimit)よりも高い時の、事前に構成された血糖降下速度時間間隔(TBGDR):
前記血糖測定値(BG)が安定期間(TStable)よりも長い持続時間にわたって前記血糖ターゲット範囲(BGTRL)内にあった時の、事前に構成された長い時間間隔(TLong):又は
食事ボーラスプログラムが作動している時の、事前に構成された食事ボーラス時間間隔(TMealBolus):
のうちの最小値に設定する段階を更に含み、
前記低血糖症時間間隔(THypo)は、前記短い時間間隔(TShort)よりも短く、当該短い時間間隔(TShort)は、前記血糖降下速度時間間隔(TBGDR)よりも短く、当該血糖降下速度時間間隔(TBGDR)は、前記長い時間間隔(TBGDR)よりも短く、前記食事ボーラス時間間隔(TMealBolus)は、当該長い時間間隔(TLong)よりも短い、
ことを特徴とする請求項1に記載の方法(700)。 - 前記静脈内インスリン注入速度(IRR)を決定する段階は、
IIR = (BG - K) * M
を計算する段階を含み、
IIRは、前記静脈内インスリン注入速度(IRR)であり、BGは、前記現在の血糖測定値(BG)であり、Kは、定数であり、Mは、乗数であり、
前記血糖パーセント降下(BG%Drop)を決定する段階は、
を計算する段階を含み、
BGPreviousは、前記以前の血糖測定値(BGPrevious)であり、BGは、前記現在の血糖測定値(BG)であり、
前記血糖降下速度(BGDropRate)を決定する段階は、
BGDropRate = (BGPrevious - BG) / (TCurrent - TPrevious)
を計算する段階を含み、
BGDropRateは、前記血糖降下速度(BGDropRate)であり、TCurrentは、現在の時間であり、TPreviousは、以前の時間である、
ことを特徴とする請求項1に記載の方法(700)。 - 前記コンピュータデバイス(112、132、142)が、前記現在の血糖測定値(BG)が血糖ターゲット範囲(BGTR)の上限(BGTRH)よりも高く、かつ、以前の血糖測定値(BGPrevious)によって除算された当該現在の血糖測定値(BG)の比が(LA)よりも低いか又はそれに等しい時に、時間間隔(TNext)間で前記乗数(M)を変化させないままに残す段階と、
前記コンピュータデバイス(112、132、142)が、前記現在の血糖測定値(BG)が前記血糖ターゲット範囲(BGTR)の上限(BGTRH)よりも高く、かつ、前記以前の血糖測定値(BGPrevious)によって除算された当該現在の血糖測定値(BG)の前記比が前記(LA)よりも高い時に、前記乗数(M)を乗数変化係数(MCF)によって乗算する段階と、
を更に含むことを特徴とする請求項3に記載の方法(700)。 - 前記定数Kは、60mg/dlに等しく、前記(LA)は、0.85であることを特徴とする請求項4に記載の方法(700)。
- 前記コンピュータデバイス(112、132、142)が、前記現在の血糖測定値(BG)が前記血糖ターゲット範囲(BGTR)の下限(BGTRL)よりも低い時に、前記乗数(M)を前記乗数変化係数(MCF)によって除算する段階
を更に含むことを特徴とする請求項4に記載の方法(700)。 - 患者(10))によって消費された実際の炭水化物の量がゼロを超えているという指示の受信に応答して、前記コンピュータデバイス(112、132、142)が前記静脈内インスリン注入速度(IRR)を増加させる段階と、前記コンピュータデバイス(112、132、142)が少なくとも2つの時間間隔(TNext)にわたって前記乗数(M)を変化させないままに維持する段階と、を更に含むことを特徴とする請求項3に記載の方法(700)。
- 食事に対する炭水化物の推定グラム数を前記コンピュータデバイス(112、132、142)で受信する段階と、
前記コンピュータデバイス(112、132、142)が、前記炭水化物の推定グラム数と炭水化物−インスリン−比(CIR)とに基づいてインスリンの単位で推定食事ボーラスを決定する段階と、
前記コンピュータデバイス(112、132、142)が、前記推定食事ボーラスと利用可能な供出時間と構成可能定数とに基づいて推定食事ボーラスインスリン速度を決定する段階と、
前記コンピュータデバイス(112、132、142)が、前記静脈内インスリン注入速度(IRR)と前記推定食事ボーラスインスリン速度との和として合計インスリン速度を決定する段階と、
を更に含むことを特徴とする請求項7に記載の方法(700)。 - 前記コンピュータデバイス(112、132、142)が、患者(10)によって消費された実際の炭水化物の量がゼロを超えているという前記指示を受信する前の食事前血糖測定値(BG1)で始まる第1食事時間部分間隔(TMealBolus1)を含む食事時間部分間隔(TMealBolusN)に、合計食事時間(TMealBolus)を分割する段階と、
前記コンピュータデバイス(112、132、142)が、順番に各食事時間部分間隔(TMealBolusN)に対する前記合計インスリン速度を決定する段階と、
を更に含むことを特徴とする請求項8に記載の方法(700)。 - 前記第1食事時間部分間隔(TMealBolus1)後の次の時間間隔(TMealBolus2)中に前記食事に対する炭水化物の実際のグラム数を前記コンピュータデバイス(112、132、142)で受信する段階と、
前記コンピュータデバイス(112、132、142)が、炭水化物の前記実際のグラム数に基づいて実際の食事ボーラスを決定する段階と、
前記コンピュータデバイス(112、132,142)が、前記推定食事ボーラスインスリン速度を経過した供出時間で乗算することによって推定供出食事ボーラスを決定する段階と、
前記コンピュータデバイス(112、132、142)が、前記実際の食事ボーラスか前記推定供出食事ボーラスと実際の供出時間との積を減算することにより、インスリンの単位で残りの食事ボーラスを決定する段階と、
前記コンピュータデバイス(112、132、142)が、前記合計食事時間内の残っている時間で除算した前記残りの食事ボーラスとして修正食事ボーラス速度を決定する段階と、
前記コンピュータデバイス(112、132、142)が、前記静脈内インスリン注入速度(IRR)と前記修正食事ボーラス速度との和として修正合計インスリン速度を決定する段階と、
を更に含むことを特徴とする請求項9に記載の方法(700)。 - 前記コンピュータデバイス(112、132、142)が、1又は2以上の食事時間部分間隔(TMealBolusN)に対して前記時間間隔(TNext)をデフォルト時間間隔(TDefault)未満に低減する段階
を更に含むことを特徴とする請求項10に記載の方法(700)。 - 前記現在の血糖測定値(BG)が安定性ターゲット範囲(BGSTR)の外側である時に、前記コンピュータデバイス(112、132、142)と通信するディスプレイ(116、143、146)上に警告を電子的に表示し、かつ、インスリンの皮下投与への移行を阻止する段階と、
前記現在の血糖測定値(BG)が閾値安定期間(TStable)未満にわたって前記安定性ターゲット範囲(BGSTR)内である時に、前記ディスプレイ(116、143、146)上に警告を電子的に表示する段階と、
を更に含むことを特徴とする請求項11に記載の方法(700)。 - 前記コンピュータデバイス(112、132、142)が、前記現在の血糖測定値(BG)が閾値安定期間(TStable)にわたって安定性ターゲット範囲(BGSTR)内である時に、前記乗数(M)に基づいてインスリンの合計1日投薬量(TDD)を決定する段階と、
前記コンピュータデバイス(112、132、142)が、インスリンの前記合計1日投薬量(TDD)の割り当てとして、皮下治療に対してインスリンの前記合計1日投薬量(TDD)の半分である1日基礎インスリンとインスリンの前記合計1日投薬量(TDD)の半分である1日食事インスリンとを含む推奨インスリン投薬量を決定する段階と、
前記コンピュータデバイス(112、132、142)が、前記コンピュータデバイス(112、132、142)と通信するディスプレイ(116、143、146)上に前記推奨インスリン投薬量を電子的に表示する段階と、
を更に含むことを特徴とする請求項3に記載の方法(700)。 - 前記コンピュータデバイス(112、132、142)が、
TDD = (BGTarget - K) * (MTrans) * 24
を計算することにより、インスリンの前記合計1日投薬量(TDD)を決定する段階を更に含み、
TDDは、インスリンの前記合計1日投薬量であり、MTransは、皮下インスリン治療への移行の処理の開始の時点での現在の乗数であり、
BGTargetは、
BGTarget = (BRTRH + BRTRL) / 2
を計算することによって決定され、
BRTRHは、血糖ターゲット範囲(BGTR)の上限(BGTRH)であり、BRTRLは、前記血糖ターゲット範囲(BGTR)の下限(BGTRL)である、
ことを特徴とする請求項13に記載の方法(700)。 - 前記コンピュータデバイス(112、132、142)が、
TDD = 0.5 * Weight
を計算することにより、患者(10)体重の関数としてインスリンの前記合計1日投薬量(TDD)を決定する段階を更に含み、
TDDは、インスリンの前記合計1日投薬量であり、 Weightは、キログラムでの患者(10)体重である、
ことを特徴とする請求項13に記載の方法(700)。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461934300P | 2014-01-31 | 2014-01-31 | |
US61/934,300 | 2014-01-31 | ||
US14/511,060 | 2014-10-09 | ||
US14/511,060 US9486580B2 (en) | 2014-01-31 | 2014-10-09 | Insulin management |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016567332A Division JP6602784B2 (ja) | 2014-01-31 | 2015-01-13 | インスリン管理 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019213866A JP2019213866A (ja) | 2019-12-19 |
JP6882383B2 true JP6882383B2 (ja) | 2021-06-02 |
Family
ID=53753955
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016567332A Active JP6602784B2 (ja) | 2014-01-31 | 2015-01-13 | インスリン管理 |
JP2019126913A Active JP6882383B2 (ja) | 2014-01-31 | 2019-07-08 | インスリン管理 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016567332A Active JP6602784B2 (ja) | 2014-01-31 | 2015-01-13 | インスリン管理 |
Country Status (8)
Country | Link |
---|---|
US (9) | US9486580B2 (ja) |
EP (2) | EP3046599B1 (ja) |
JP (2) | JP6602784B2 (ja) |
AU (1) | AU2015211352B2 (ja) |
CA (1) | CA2926761C (ja) |
HK (1) | HK1222357A1 (ja) |
IL (1) | IL246936A (ja) |
WO (1) | WO2015116371A1 (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
WO2012058694A2 (en) | 2010-10-31 | 2012-05-03 | Trustees Of Boston University | Blood glucose control system |
TW201333870A (zh) | 2011-12-21 | 2013-08-16 | 艾登工具股份有限公司 | 決定病人胰島素療法的系統及方法 |
US9561324B2 (en) | 2013-07-19 | 2017-02-07 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
GB2523989B (en) | 2014-01-30 | 2020-07-29 | Insulet Netherlands B V | Therapeutic product delivery system and method of pairing |
WO2015116524A1 (en) | 2014-01-31 | 2015-08-06 | Trustees Of Boston University | Offline glucose control based on preceding periods |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
US9792373B2 (en) * | 2014-12-31 | 2017-10-17 | Facebook, Inc. | Systems and methods to determine trending topics for a user based on social graph data |
EP3258991B1 (en) | 2015-02-18 | 2020-10-21 | Insulet Corporation | Fluid delivery and infusion devices, and methods of use thereof |
JP2018525093A (ja) | 2015-08-07 | 2018-09-06 | トラスティーズ オブ ボストン ユニバーシティ | グルコース目標の自動適合を備えたグルコース制御システム |
JP6858751B2 (ja) * | 2015-08-20 | 2021-04-14 | アセコー インコーポレイテッド | 糖尿病管理療法アドバイザ |
WO2017123525A1 (en) | 2016-01-13 | 2017-07-20 | Bigfoot Biomedical, Inc. | User interface for diabetes management system |
CN112933333B (zh) | 2016-01-14 | 2023-03-28 | 比格福特生物医药公司 | 调整胰岛素输送速率 |
US10610643B2 (en) | 2016-01-14 | 2020-04-07 | Bigfoot Biomedical, Inc. | Occlusion resolution in medication delivery devices, systems, and methods |
US20170263156A1 (en) * | 2016-03-08 | 2017-09-14 | Quattro Folia Oy | Method and system for recommending a set of insulin dosages for a patient |
MA45527A (fr) | 2016-06-30 | 2019-05-08 | Novo Nordisk As | Systèmes et procédés destinés à l'analyse des données d'adhérence de régime d'insuline |
US20190333621A1 (en) * | 2016-06-30 | 2019-10-31 | Novo Nordisk A/S | System and methods for analysis of insulin regimen adherence data |
JP6983871B2 (ja) | 2016-08-25 | 2021-12-17 | ノボ・ノルデイスク・エー/エス | 基礎インスリン滴定のスターターキット |
WO2018037080A1 (en) * | 2016-08-25 | 2018-03-01 | Novo Nordisk A/S | Starter kit for basal insulin titration |
EP3515535A1 (en) | 2016-09-23 | 2019-07-31 | Insulet Corporation | Fluid delivery device with sensor |
EP3549133A1 (en) | 2016-11-29 | 2019-10-09 | Novo Nordisk A/S | Starter kit for basal rate titration |
US11096624B2 (en) | 2016-12-12 | 2021-08-24 | Bigfoot Biomedical, Inc. | Alarms and alerts for medication delivery devices and systems |
US10881792B2 (en) | 2017-01-13 | 2021-01-05 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
US11027063B2 (en) | 2017-01-13 | 2021-06-08 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
EP3582830A4 (en) * | 2017-02-15 | 2020-12-09 | University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group | SYSTEM AND METHOD FOR BINDING THE BODY MASS INDEX TO A DIFFERENT PATIENT PSYCHOLOGICAL STRESS EFFECT ON GLYCEMIA DYNAMICS IN PATIENTS WITH INSULINE DEPENDENT DIABETES |
EP3596783A4 (en) | 2017-03-20 | 2020-12-16 | Viasat, Inc. | HIGH FREQUENCY SEAL AT AN INTERFACE OF WAVE GUIDE BLOCKS |
USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
CN112236826B (zh) | 2018-05-04 | 2024-08-13 | 英赛罗公司 | 基于控制算法的药物输送系统的安全约束 |
US11147922B2 (en) | 2018-07-13 | 2021-10-19 | Iowa State University Research Foundation, Inc. | Feedback predictive control approach for processes with time delay in the manipulated variable |
CA3112209C (en) | 2018-09-28 | 2023-08-29 | Insulet Corporation | Activity mode for artificial pancreas system |
US11565039B2 (en) | 2018-10-11 | 2023-01-31 | Insulet Corporation | Event detection for drug delivery system |
USD920343S1 (en) | 2019-01-09 | 2021-05-25 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface associated with insulin delivery |
AU2020314831A1 (en) | 2019-07-16 | 2022-02-24 | Beta Bionics, Inc. | Blood glucose control system |
AU2020314752A1 (en) | 2019-07-16 | 2022-02-24 | Beta Bionics, Inc. | Blood glucose control system |
US11957876B2 (en) | 2019-07-16 | 2024-04-16 | Beta Bionics, Inc. | Glucose control system with automated backup therapy protocol generation |
US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
JP2022551265A (ja) * | 2019-10-04 | 2022-12-08 | ベータ バイオニクス,インコーポレイテッド | 血中グルコース制御システム |
EP4069082B1 (en) | 2019-12-06 | 2024-06-05 | Insulet Corporation | Techniques and devices providing adaptivity and personalization in diabetes treatment |
US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
WO2021138171A1 (en) * | 2019-12-30 | 2021-07-08 | Roche Diabetes Care, Inc. | Computer-implemented diabetes management methods |
JP7512395B2 (ja) | 2020-01-06 | 2024-07-08 | インスレット コーポレイション | 持続する残差に基づく食事および/または運動行為の予測 |
US20210236726A1 (en) * | 2020-02-03 | 2021-08-05 | Insulet Corporation | Insulin delivery using actual user insulin delivery amounts to accurately predict quantity and timing of insulin reservoir refills |
US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
US11986630B2 (en) | 2020-02-12 | 2024-05-21 | Insulet Corporation | Dual hormone delivery system for reducing impending hypoglycemia and/or hyperglycemia risk |
US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
JP2023513805A (ja) * | 2020-02-14 | 2023-04-03 | デックスコム・インコーポレーテッド | 意思決定サポートおよび治療投与システム |
US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
KR102474292B1 (ko) * | 2020-03-23 | 2022-12-06 | 이오플로우(주) | 약액 주입 제어 방법 및 컴퓨터 프로그램 |
US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
US12121700B2 (en) | 2020-07-22 | 2024-10-22 | Insulet Corporation | Open-loop insulin delivery basal parameters based on insulin delivery records |
US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
WO2022072332A1 (en) | 2020-09-30 | 2022-04-07 | Insulet Corporation | Drug delivery device with integrated optical-based glucose monitor |
US12115351B2 (en) | 2020-09-30 | 2024-10-15 | Insulet Corporation | Secure wireless communications between a glucose monitor and other devices |
US20220189603A1 (en) | 2020-12-07 | 2022-06-16 | Beta Bionics, Inc. | Medicament pumps and control systems for managing glucose control therapy data of a subject |
US11160925B1 (en) | 2021-01-29 | 2021-11-02 | Insulet Corporation | Automatic drug delivery system for delivery of a GLP-1 therapeutic |
US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
FR3125696A1 (fr) * | 2021-07-27 | 2023-02-03 | Pkvitality | Gestion des alertes dans un procédé de détection de la concentration d’un analyte contenu dans un fluide corporel d’un individu |
EP4409581A1 (en) | 2021-09-27 | 2024-08-07 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
US12070313B2 (en) | 2022-07-05 | 2024-08-27 | Biolinq Incorporated | Sensor assembly of a microneedle array-based continuous analyte monitoring device |
WO2024089529A1 (en) | 2022-10-28 | 2024-05-02 | Medtronic, Inc. | Medical device implantation by perioperative patient evaluation preparation |
WO2024147928A1 (en) | 2023-01-06 | 2024-07-11 | Insulet Corporation | Automatically or manually initiated meal bolus delivery with subsequent automatic safety constraint relaxation |
WO2024178575A1 (zh) * | 2023-02-28 | 2024-09-06 | 上海移宇科技有限公司 | 根据实际血糖值的差值的变化率进行自动检测的方法及闭环人工胰腺 |
Family Cites Families (385)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US561422A (en) | 1896-06-02 | Paul minnis | ||
US4055175A (en) | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
FR2387659A1 (fr) | 1977-04-21 | 1978-11-17 | Armines | Dispositif de controle et regulation de la glycemie |
US4151845A (en) | 1977-11-25 | 1979-05-01 | Miles Laboratories, Inc. | Blood glucose control apparatus |
US4403984A (en) | 1979-12-28 | 1983-09-13 | Biotek, Inc. | System for demand-based adminstration of insulin |
US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
US4981779A (en) | 1986-06-26 | 1991-01-01 | Becton, Dickinson And Company | Apparatus for monitoring glucose |
US5216597A (en) | 1987-05-01 | 1993-06-01 | Diva Medical Systems Bv | Diabetes therapy management system, apparatus and method |
US4850959A (en) | 1988-08-02 | 1989-07-25 | Bioresearch, Inc. | Bioelectrochemical modulation of biological functions using resonant/non-resonant fields synergistically |
US4911168A (en) | 1989-01-13 | 1990-03-27 | Pacesetter Infusion, Ltd. | Method of screening and selecting intraperitoneal medication infusion pump candidates |
US4947845A (en) | 1989-01-13 | 1990-08-14 | Pacesetter Infusion, Ltd. | Method of maximizing catheter longevity in an implantable medication infusion system |
US5101814A (en) | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5091190A (en) | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
US5251126A (en) | 1990-10-29 | 1993-10-05 | Miles Inc. | Diabetes data analysis and interpretation method |
GB9024771D0 (en) | 1990-11-14 | 1991-01-02 | Axis Research | Assay |
GB9104037D0 (en) | 1991-02-26 | 1991-04-10 | Hospital For Sick The Children | Process for the phosphorylation of insulin |
SE9101381D0 (sv) | 1991-05-07 | 1991-05-07 | Tomas Moks | Peptide hormone solution |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US7624028B1 (en) | 1992-11-17 | 2009-11-24 | Health Hero Network, Inc. | Remote health monitoring and maintenance system |
US6186145B1 (en) | 1994-05-23 | 2001-02-13 | Health Hero Network, Inc. | Method for diagnosis and treatment of psychological and emotional conditions using a microprocessor-based virtual reality simulator |
EP0642350A4 (en) | 1993-01-25 | 1995-06-28 | Beth Israel Hospital | PROCESS FOR MODIFICATION, DIAGNOSIS AND SCREENING OF IGF-I SENSITIVE CELL BARRIER CHARACTERISTICS. |
US5917052A (en) | 1994-09-28 | 1999-06-29 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
US5614224A (en) | 1995-04-20 | 1997-03-25 | Womack; Rick W. | Nutritional supplement for diabetics |
US5665065A (en) * | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
MY115050A (en) | 1995-10-16 | 2003-03-31 | Mead Johnson Nutrition Co | Diabetic nutritional product having controlled absorption of carbohydrate |
US5821217A (en) | 1995-10-27 | 1998-10-13 | Beth Israel Deaconess Medical Center, Inc. | Enteral formulation: low in fat and containing protein hydrolysates |
ATE278801T1 (de) | 1995-11-22 | 2004-10-15 | Medtronic Minimed Inc | Detektion von biologischen molekülen unter verwendung von chemischer amplifikation und optischem sensor |
EP0910578A2 (en) | 1996-01-19 | 1999-04-28 | The Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
US5830180A (en) * | 1996-07-17 | 1998-11-03 | Aquarius Medical Corporation | Fluid management system for arthroscopic surgery |
US8734339B2 (en) | 1996-12-16 | 2014-05-27 | Ip Holdings, Inc. | Electronic skin patch for real time monitoring of cardiac activity and personal health management |
US6391312B1 (en) | 1997-01-23 | 2002-05-21 | Sumitomo Pharmaceuticals Co., Limited | Remedies for diabetes |
US20010002269A1 (en) | 1997-05-06 | 2001-05-31 | Zhao Iris Ginron | Multi-phase food & beverage |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US5929055A (en) | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
WO1999017610A1 (en) | 1997-10-02 | 1999-04-15 | The Regents Of The University Of California | Protein delivery by secretory gland expression |
US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
EP1051141A4 (en) | 1998-01-09 | 2001-05-23 | Amylin Pharmaceuticals Inc | INSULIN CONTAINING PHARMACEUTICAL COMPOSITIONS CONTAINING AN AMYLINAGONIST |
AU2989699A (en) | 1998-03-05 | 1999-09-20 | Universal Health-Watch, Inc. | Apparatus to non-invasively measure glucose or other constituents in aqueous humor using infra-red spectroscopy |
US6024699A (en) | 1998-03-13 | 2000-02-15 | Healthware Corporation | Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients |
WO1999051225A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antidiabetic agents |
AU3999699A (en) | 1998-05-19 | 1999-12-06 | Sdg, Inc. | Targeted liposomal drug delivery system |
US6537806B1 (en) | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
US6554798B1 (en) * | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
WO2000018392A1 (en) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
US6615081B1 (en) | 1998-10-26 | 2003-09-02 | Birinder R. Boveja | Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator |
US6540672B1 (en) | 1998-12-09 | 2003-04-01 | Novo Nordisk A/S | Medical system and a method of controlling the system for use by a patient for medical self treatment |
US20070293742A1 (en) | 1998-11-30 | 2007-12-20 | Novo Nordisk A/S | Medical System And A Method Of Controlling The System For Use By A Patient For Medical Self Treatment |
CZ20011702A3 (cs) | 1998-11-30 | 2001-10-17 | Novo Nordisk A/S | Postup a systém pomáhající uľivateli při samoléčbě, přičemľ uvedená samoléčba spočívá v mnoľství činností |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
CA2370302A1 (en) | 1999-04-27 | 2000-11-02 | Benjamin Lee Hughes | Insulin crystals for pulmonary administration |
US6669663B1 (en) | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US6890568B2 (en) | 1999-05-24 | 2005-05-10 | Grant Pierce | Method for management of blood glucose levels |
US7806886B2 (en) | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
AU5844300A (en) | 1999-06-04 | 2000-12-28 | Indian Council Of Medical Research | Eugenia jambolina fruit extracts for treating diabetes |
AU5453300A (en) | 1999-06-29 | 2001-01-31 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
CA2381539A1 (en) | 1999-09-15 | 2001-03-22 | Medtronic Minimed, Inc. | Glucose sensing molecules having selected fluorescent properties |
DE19954233A1 (de) | 1999-11-11 | 2001-05-31 | Nutricia Nv | Diabetikernahrung |
US6925393B1 (en) * | 1999-11-18 | 2005-08-02 | Roche Diagnostics Gmbh | System for the extrapolation of glucose concentration |
US6810290B2 (en) * | 2000-01-21 | 2004-10-26 | Medtronic Minimed, Inc. | Ambulatory medical apparatus with hand held communication device |
US6572542B1 (en) | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
AU5104601A (en) | 2000-03-29 | 2001-10-08 | Univ Virginia | Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data |
JP4580542B2 (ja) | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
CA2409501A1 (en) | 2000-05-25 | 2001-11-29 | Healthetech, Inc. | Physiological monitoring using wrist-mounted device |
US6605039B2 (en) | 2000-07-24 | 2003-08-12 | Medtronic, Inc. | Cell-based biosensors suitable for implantable medical device applications |
AU2000265109A1 (en) | 2000-08-02 | 2002-02-13 | Pharmanutrients | Method and compositions for prevention and/or treatment of diabetes and glucose modulation |
US6365176B1 (en) | 2000-08-08 | 2002-04-02 | Functional Foods, Inc. | Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy |
WO2002024065A1 (en) | 2000-09-22 | 2002-03-28 | Knobbe, Lim & Buckingham | Method and apparatus for real-time estimation and control of pysiological parameters |
WO2002036139A1 (en) | 2000-11-01 | 2002-05-10 | Biovan, Inc. | Method for management of blood glucose levels |
EP1346685B1 (en) | 2000-11-30 | 2008-04-16 | ARKRAY, Inc. | Measuring device equipped with comment input function |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
PL359266A1 (en) | 2001-02-08 | 2004-08-23 | Inverness Medical Limited | A personal condition management system |
US6927246B2 (en) | 2001-02-15 | 2005-08-09 | Medtronic Minimed, Inc. | Polymers functionalized with fluorescent boronate motifs and methods for making them |
US7041468B2 (en) * | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
JP5135568B2 (ja) | 2001-06-18 | 2013-02-06 | ネプチューン テクノロジーズ アンド バイオリソーシイズ インク | 心臓血管疾患、関節炎、皮膚ガン、糖尿病、月経前症候群および経皮送達の予防および/または治療のためのオキアミおよび/または海洋生物の抽出物 |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
JP3775263B2 (ja) | 2001-08-10 | 2006-05-17 | ニプロ株式会社 | 記録媒体およびこの記録媒体を用いた血糖測定システム |
US20040054263A1 (en) | 2001-08-20 | 2004-03-18 | Piet Moerman | Wireless diabetes management devices and methods for using the same |
US6691043B2 (en) * | 2001-08-28 | 2004-02-10 | Maxi-Med, Llc | Bolus calculator |
US6740072B2 (en) | 2001-09-07 | 2004-05-25 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
MY135783A (en) | 2001-09-07 | 2008-06-30 | Meiji Dairies Corp | Nutritional composition for controlling blood sugar level |
US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
KR20030025200A (ko) | 2001-09-19 | 2003-03-28 | (주)바이오니아 | 아밀라제의 활성을 억제할 수 있는 옥수수 추출물, 이를함유하는 비만증 또는 당뇨병 치료 또는 예방용 의약적조성물 및 식품 첨가물 그리고 그들의 제조방법 |
US7204823B2 (en) | 2001-12-19 | 2007-04-17 | Medtronic Minimed, Inc. | Medication delivery system and monitor |
WO2003053460A1 (en) | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
WO2003061643A1 (es) | 2002-01-25 | 2003-07-31 | Laboratorios Silanes, S.A. De C.V. | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2 |
US20030199445A1 (en) | 2002-02-07 | 2003-10-23 | Knudsen Lotte Bjerre | Use of GLP-1 compound for treatment of critically ill patients |
US7108680B2 (en) | 2002-03-06 | 2006-09-19 | Codman & Shurtleff, Inc. | Closed-loop drug delivery system |
TW200304372A (en) | 2002-03-20 | 2003-10-01 | Kanegafuchi Chemical Ind | Compositions for diabetes |
GB0206792D0 (en) | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
WO2003090614A1 (fr) | 2002-04-25 | 2003-11-06 | Matsushita Electric Industrial Co., Ltd. | Dispositif de determination de dose, injecteur et systeme de gestion sanitaire |
AU2003228777C1 (en) | 2002-04-30 | 2009-08-13 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US20060264886A9 (en) | 2002-05-06 | 2006-11-23 | Pettis Ronald J | Method for altering insulin pharmacokinetics |
JP2003319758A (ja) | 2002-05-07 | 2003-11-11 | Unitika Ltd | D−グルコース吸収抑制方法及びd−グルコース吸収抑制剤 |
US20040018533A1 (en) | 2002-06-04 | 2004-01-29 | Adam Gail Isabel Reid | Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions |
AU2003248794B2 (en) | 2002-06-27 | 2007-10-04 | Harkness Pharmaceuticals, Inc. | Therapeutic methods for reducing fat deposition and treating associated conditions |
US20050267195A1 (en) | 2002-06-28 | 2005-12-01 | Imao Mikoshiba | Drug composition for blood sugar control |
EP1382363A1 (en) | 2002-07-15 | 2004-01-21 | Novo Nordisk A/S | Closed loop system for controlling blood glucose levels |
FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
US8571801B2 (en) | 2002-08-28 | 2013-10-29 | Atkins Nutritionals, Inc. | Methods and systems for determining and controlling glycemic responses |
JP2004095048A (ja) | 2002-08-30 | 2004-03-25 | Toshiba Corp | 不揮発性半導体メモリ |
US7404796B2 (en) | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
US20040092590A1 (en) | 2002-09-27 | 2004-05-13 | Linda Arterburn | Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid |
CA2505639C (en) | 2002-10-11 | 2012-07-03 | Becton, Dickinson And Company | System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (id) delivery device |
US7137951B2 (en) | 2002-10-23 | 2006-11-21 | Joseph Pilarski | Method of food and insulin dose management for a diabetic subject |
US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
WO2004084820A2 (en) * | 2003-03-19 | 2004-10-07 | Harry Hebblewhite | Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
CA2519249C (en) | 2003-03-19 | 2012-11-27 | Harry Hebblewhite | Method and system for determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
US7504118B2 (en) | 2003-04-11 | 2009-03-17 | Fhg Corporation | Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport |
JP2005029570A (ja) | 2003-06-16 | 2005-02-03 | Tokiwa Shokubutsu Kagaku Kenkyusho:Kk | コロソリン酸の製造方法 |
US20050054818A1 (en) | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
WO2005041022A1 (en) | 2003-10-24 | 2005-05-06 | Judy Singley | Method, system, and computer program for performing carbohydrate/insulin calculation based upon food weight |
KR100567837B1 (ko) | 2003-10-24 | 2006-04-05 | 케이제이헬스케어 주식회사 | 혈당측정이 가능한 이동통신단말기와 결합되는 인슐린펌프와, 인슐린 펌프의 제어정보 전송을 위한 네트워크시스템 |
US20050096637A1 (en) | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Sensing food intake |
US20080119421A1 (en) | 2003-10-31 | 2008-05-22 | Jack Tuszynski | Process for treating a biological organism |
EP1690519A1 (en) | 2003-11-04 | 2006-08-16 | Meiji Dairies Corporation | Alpha-glucosidase activity inhibitor |
JP4704351B2 (ja) | 2003-11-06 | 2011-06-15 | ライフスキャン・インコーポレイテッド | イベント通知手段を備えた薬剤導入ペン |
EP1711101A1 (en) | 2004-01-15 | 2006-10-18 | Glucon Inc. | Wearable glucometer |
WO2006004574A2 (en) | 2004-02-19 | 2006-01-12 | Abbott Laboratories | Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
WO2005081119A2 (en) | 2004-02-19 | 2005-09-01 | Edward Henry Mathews | Interactive diabetes education system |
WO2005081170A2 (en) | 2004-02-19 | 2005-09-01 | Edward Henry Mathews | Diabetes management and patient database system via mobile communication device |
WO2005081171A2 (en) | 2004-02-19 | 2005-09-01 | Edward Henry Mathews | Insulin bolus calculator for mobile communication device |
WO2005081173A1 (en) | 2004-02-19 | 2005-09-01 | Edward Henry Mathews | Diabetes slide ruler for blood glucose control |
US7651845B2 (en) | 2004-05-13 | 2010-01-26 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
WO2005110222A1 (en) | 2004-05-18 | 2005-11-24 | Okto Medical Appliance Co., Ltd. | Blood sugar control system and medical treatment method using the same |
WO2006006286A1 (ja) | 2004-07-09 | 2006-01-19 | Meiji Dairies Corporation | Pparおよび/またはppar関連因子産生増強組成物 |
WO2006022638A1 (en) | 2004-07-22 | 2006-03-02 | Sequenom, Inc. | Methods for identifying risk of type ii diabetes and treatments thereof |
WO2006022636A1 (en) | 2004-07-22 | 2006-03-02 | Sequenom, Inc. | Methods for identifying risk of type ii diabetes and treatments thereof |
WO2006022629A1 (en) | 2004-07-22 | 2006-03-02 | Sequenom, Inc. | Methods of identifying risk of type ii diabetes and treatments thereof |
EP1773860A4 (en) | 2004-07-22 | 2009-05-06 | Sequenom Inc | METHOD FOR IDENTIFYING THE RISK OF TYPE II DIABETES AND TREATING THEREOF |
WO2006022619A2 (en) | 2004-07-22 | 2006-03-02 | Sequenom, Inc. | Methods for identifying risk of type ii diabetes and treatments thereof |
WO2006022633A1 (en) | 2004-07-22 | 2006-03-02 | Sequenom, Inc. | Methods for identifying a risk of type ii diabetes and treatments thereof |
WO2006022634A1 (en) | 2004-07-22 | 2006-03-02 | Sequenom, Inc. | Methods for identifying risk of type ii diabetes and treatments thereof |
US20060040003A1 (en) | 2004-08-10 | 2006-02-23 | Alvin Needleman | Dietary supplement for supressing appetite, enhancing and extending satiety, improving glycemic control, and stimulant free |
US20070060549A1 (en) | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20120213886A1 (en) | 2004-08-25 | 2012-08-23 | U.S. Dept. Of Veterans Affairs | Compositions and Methods to Lower Glycohemoglobin Levels |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
US7291107B2 (en) | 2004-08-26 | 2007-11-06 | Roche Diagnostics Operations, Inc. | Insulin bolus recommendation system |
EP1698898A3 (en) | 2004-09-21 | 2006-10-11 | Foundation of Biomedical Research of the Academy of Athens | Prognostic, diagnostic and therapeutic significance in detecting and using TIN-antigen (Tubulo-Interstitial nephritis antigen) and its segments |
US20060078593A1 (en) | 2004-09-27 | 2006-04-13 | Strozier Deborah C | Nutritional compostions comprising a soluble viscous fiber in a solid crisp matrix |
US20060106014A1 (en) | 2004-10-14 | 2006-05-18 | Sekhar Boddupalli | Methods for treating diabetes |
US8117020B2 (en) | 2004-12-03 | 2012-02-14 | Roche Diagnostics Operations, Inc. | Method to determine the degree and stability of blood glucose control in patients with diabetes mellitus via creation and continuous updating of new statistical indicators |
ITMI20050010A1 (it) | 2005-01-05 | 2006-07-06 | Aboca S P A | Composizioni farmaceutiche nutraceutiche dietetiche nutrizionali a base di fibre vegetali |
CA2491763A1 (en) | 2005-01-06 | 2006-07-06 | Tassos P. Anastassiades | Blood glucose control with n-acylated glucosamines |
WO2006079124A2 (en) | 2005-01-24 | 2006-07-27 | Edward Henry Mathews | Apparatus and method for predicting the effect of ingested foodstuff or exercise on blood sugar level of patient and suggesting a corrective action |
US20060173260A1 (en) | 2005-01-31 | 2006-08-03 | Gmms Ltd | System, device and method for diabetes treatment and monitoring |
WO2006091918A2 (en) | 2005-02-23 | 2006-08-31 | Streck, Inc. | Process, composition and kit for providing a stable whole blood calibrator/control |
US20060188995A1 (en) | 2005-02-24 | 2006-08-24 | Ryan Wayne L | Process, composition and kit for providing a stable whole blood calibrator/control |
KR100750988B1 (ko) | 2005-03-18 | 2007-08-22 | 주식회사 유니젠 | 천연물유래 진세노사이드를 포함하는 당뇨 또는혈당조절이상의 예방 또는 치료용 약학 조성물 |
BRPI0500959A (pt) | 2005-03-23 | 2006-11-21 | Unicamp | uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos |
US20120065482A1 (en) | 2005-04-08 | 2012-03-15 | Mark Ries Robinson | Determination of blood pump system performance and sample dilution using a property of fluid being transported |
US20090054753A1 (en) | 2007-08-21 | 2009-02-26 | Mark Ries Robinson | Variable Sampling Interval for Blood Analyte Determinations |
MX2007013486A (es) | 2005-04-27 | 2008-03-14 | Jallal Messadek | Combinaciones de insulinas. |
US20060263450A1 (en) | 2005-05-17 | 2006-11-23 | Julius Oben | Method and composition for reducing body weight and improving control of body lipids |
US7509156B2 (en) | 2005-05-18 | 2009-03-24 | Clarian Health Partners, Inc. | System for managing glucose levels in patients with diabetes or hyperglycemia |
WO2006130901A1 (en) | 2005-06-07 | 2006-12-14 | Bayer Healthcare Ag | Control of metabolic abnormalities |
US8251904B2 (en) | 2005-06-09 | 2012-08-28 | Roche Diagnostics Operations, Inc. | Device and method for insulin dosing |
EP1962820A2 (en) | 2005-06-24 | 2008-09-03 | DSMIP Assets B.V. | Medicament for the treatment of impaired glucose metabolism |
PL1921981T3 (pl) | 2005-07-29 | 2012-11-30 | Univ Degli Studi Udine | Urządzenie i sposób do zapobiegania hipoglikemii u pacjenta będącego człowiekiem z cukrzycą typu 1 podczas aktywności fizycznej |
WO2007016600A2 (en) | 2005-08-01 | 2007-02-08 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
US20070078314A1 (en) | 2005-09-30 | 2007-04-05 | Grounsell Richard L | System and method for measuring and predicting insulin dosing rates |
US7704226B2 (en) | 2005-11-17 | 2010-04-27 | Medtronic Minimed, Inc. | External infusion device with programmable capabilities to time-shift basal insulin and method of using the same |
US20070168224A1 (en) | 2005-11-22 | 2007-07-19 | Letzt Alan M | Advanced diabetes management system (adms) |
US8557274B2 (en) | 2005-12-06 | 2013-10-15 | Purdue Research Foundation | Slowly digesting starch and fermentable fiber |
US8057840B2 (en) | 2006-01-25 | 2011-11-15 | Tate & Lyle Ingredients Americas Llc | Food products comprising a slowly digestible or digestion resistant carbohydrate composition |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US7824333B2 (en) | 2006-03-31 | 2010-11-02 | Lifescan, Inc. | Diabetes management methods and systems |
GB2436873A (en) | 2006-04-07 | 2007-10-10 | Univ Cambridge Tech | Blood glucose monitoring systems |
US20070282186A1 (en) | 2006-05-02 | 2007-12-06 | Adrian Gilmore | Blood glucose monitor with an integrated data management system |
US20070287923A1 (en) * | 2006-05-15 | 2007-12-13 | Charles Adkins | Wrist plethysmograph |
US8548544B2 (en) | 2006-06-19 | 2013-10-01 | Dose Safety | System, method and article for controlling the dispensing of insulin |
CA2655566A1 (en) | 2006-06-30 | 2008-01-10 | Healthy Interactions, Inc. | System, method, and device for providing health information |
US20090312250A1 (en) | 2006-07-14 | 2009-12-17 | Postech Academy-Industry Foundation | Epidermal growth factor increasing insulin secretion and lowering blood glucose |
JP5299900B2 (ja) | 2006-07-28 | 2013-09-25 | 国立大学法人金沢大学 | 糖尿病関連肝臓由来分泌タンパク質の2型糖尿病または血管障害の診断または治療への利用 |
US9056165B2 (en) | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
US20080172030A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having aweekly schedule |
US20080172027A1 (en) * | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having basal rate testing features |
US8204729B2 (en) | 2006-11-01 | 2012-06-19 | Philip Michael Sher | Device for predicting and managing blood glucose by analyzing the effect of, and controlling, pharmacodynamic insulin equivalents |
US8721584B2 (en) | 2006-11-02 | 2014-05-13 | The University Of North Carolina At Chapel Hill | Methods and systems for determining an intravenous insulin infusion rate to correct hyperglycemia of a patient, to maintain euglycemia of a patient, and to prevent hypoglycemia of a patient |
US20080306353A1 (en) | 2006-11-03 | 2008-12-11 | Douglas Joel S | Calculation device for metabolic control of critically ill and/or diabetic patients |
US20080119705A1 (en) | 2006-11-17 | 2008-05-22 | Medtronic Minimed, Inc. | Systems and Methods for Diabetes Management Using Consumer Electronic Devices |
WO2008067245A2 (en) | 2006-11-29 | 2008-06-05 | University Of Maryland, Baltimore | Determining insulin pump rate for tight glycemic control |
US20080139910A1 (en) | 2006-12-06 | 2008-06-12 | Metronic Minimed, Inc. | Analyte sensor and method of using the same |
US20080214919A1 (en) | 2006-12-26 | 2008-09-04 | Lifescan, Inc. | System and method for implementation of glycemic control protocols |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US7734323B2 (en) | 2007-01-24 | 2010-06-08 | Smiths Medical Asd, Inc. | Correction factor testing using frequent blood glucose input |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
US20080234943A1 (en) | 2007-03-20 | 2008-09-25 | Pinaki Ray | Computer program for diabetes management |
US20080249386A1 (en) | 2007-04-04 | 2008-10-09 | Pronia Medical Systems, Llc | Systems, Methods, and Computer Program Product for Improved Management of Medical Procedures for Patients on Medical Protocols |
US20080255707A1 (en) | 2007-04-10 | 2008-10-16 | Hebblewhite Harry R | Method and system for categorizing blood glucose tests at test time in a portable device or later in a downloading program and then analyzing the categories separately |
CA2684457A1 (en) | 2007-04-19 | 2008-10-30 | C.G.M.3 Ltd | Device system and method for monitoring and controlling blood analyte levels |
US20080300572A1 (en) * | 2007-06-01 | 2008-12-04 | Medtronic Minimed, Inc. | Wireless monitor for a personal medical device system |
EP2518655B1 (en) | 2007-06-21 | 2019-11-20 | Roche Diabetes Care GmbH | Device and method for preventing hypoglycemia |
EP2171568B1 (en) | 2007-06-29 | 2018-05-30 | Roche Diabetes Care GmbH | User interface features for an electronic device |
US20090036753A1 (en) | 2007-07-31 | 2009-02-05 | King Allen B | Continuous glucose monitoring-directed adjustments in basal insulin rate and insulin bolus dosing formulas |
JP2010536806A (ja) | 2007-08-21 | 2010-12-02 | エイティピー・マーケティング・アンド・プロモーション・アクチェンゲゼルシャフト | 糖尿病患者における血糖値をコントロールするための薬草製剤 |
US7943163B2 (en) | 2007-08-22 | 2011-05-17 | Response Scientific, Inc. | Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes |
US7998069B2 (en) | 2007-09-11 | 2011-08-16 | Roche Diagnostics Operations, Inc. | Mask algorithms for health management systems |
TWI348910B (en) | 2007-10-29 | 2011-09-21 | Univ Taipei Medical | Composition for controlling blood glucose and method thereof |
EP2273400A1 (en) * | 2007-12-10 | 2011-01-12 | Bayer Healthcare LLC | Method and system for managing health data |
US20100262434A1 (en) | 2007-12-13 | 2010-10-14 | Shaya Steven A | Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose |
US9199031B2 (en) | 2007-12-26 | 2015-12-01 | Ofer Yodfat | Maintaining glycemic control during exercise |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
US20090238879A1 (en) | 2008-01-24 | 2009-09-24 | Northwestern University | Delivery scaffolds and related methods of use |
US20090214511A1 (en) | 2008-02-21 | 2009-08-27 | Trung Hong Tran | Digestible compositions of inulin for managing blood glucose levels |
US8317699B2 (en) | 2008-02-29 | 2012-11-27 | Roche Diagnostics Operations, Inc. | Device and method for assessing blood glucose control |
US20090240127A1 (en) | 2008-03-20 | 2009-09-24 | Lifescan, Inc. | Methods of determining pre or post meal time slots or intervals in diabetes management |
US20090242399A1 (en) | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
US20090247982A1 (en) | 2008-03-27 | 2009-10-01 | Lifescan Inc. | Medical Device Mechanical Pump |
US8185412B1 (en) | 2008-03-28 | 2012-05-22 | Mahesh Harpale | Method and apparatus for chronic care treatment control with custom named-type factors and user estimation error correction |
WO2009124111A2 (en) | 2008-04-01 | 2009-10-08 | Trustees Of Boston University | Glucose sensor employing semiconductor nanoelectronic device |
EP2260462B1 (en) | 2008-04-04 | 2018-12-19 | Hygieia, Inc. | System for optimizing a patient's insulin dosage regimen |
US9220456B2 (en) | 2008-04-04 | 2015-12-29 | Hygieia, Inc. | Systems, methods and devices for achieving glycemic balance |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
US20100256047A1 (en) | 2009-04-03 | 2010-10-07 | Lifescan, Inc. | Analyte Measurement and Management Device and Associated Methods |
US20090281519A1 (en) | 2008-05-12 | 2009-11-12 | Rao R Harsha | Automated system and method for diabetes control |
JP5361243B2 (ja) | 2008-05-13 | 2013-12-04 | キヤノン株式会社 | 光断層画像撮像装置 |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
MX2011000135A (es) | 2008-06-26 | 2011-02-25 | Silanes Sa De Cv Lab | Una nueva sal de glicinato de metformina para el control de la glucosa en sangre. |
IT1396465B1 (it) | 2008-07-10 | 2012-12-14 | B G Informatica S R L | Metodo per la definizione e la gestione interattiva di un trattamento per il controllo del tasso glicemico nel paziente diabetico e dispositivo integrato che attua tale metodo |
WO2010009382A2 (en) | 2008-07-18 | 2010-01-21 | Lifescan, Inc. | Analyte measurement and management device and associated methods |
KR100918776B1 (ko) | 2009-04-20 | 2009-09-24 | 계명대학교 산학협력단 | 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물 |
TWI494123B (zh) | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
WO2010021761A1 (en) | 2008-08-20 | 2010-02-25 | Bayer Healthcare Llc | Health management supply organizing system and methods |
EP2355669A2 (en) | 2008-09-23 | 2011-08-17 | Rubicon Research Private Limited | Dietary fiber compositions |
EP2179661A1 (en) | 2008-10-23 | 2010-04-28 | Generale Biscuit | Biscuit comprising guar gum in a rod-like form |
WO2010056718A2 (en) | 2008-11-11 | 2010-05-20 | Hygieia, Inc. | Apparatus and system for diabetes management |
US8527208B2 (en) | 2008-11-17 | 2013-09-03 | Roche Diagnostics International Ag | Prandial blood glucose excursion optimization method via computation of time-varying optimal insulin profiles and system thereof |
US20120011125A1 (en) | 2008-12-23 | 2012-01-12 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
US20100161346A1 (en) | 2008-12-24 | 2010-06-24 | Kristen Getschmann | Systems and Methods for Providing Bolus Dosage Recommendations |
US20100160740A1 (en) | 2008-12-24 | 2010-06-24 | Gary Cohen | Use of Patterns in a Therapy Management System |
US20100174553A1 (en) | 2008-12-24 | 2010-07-08 | Medtronic Minimed, Inc. | Diabetes Therapy Management System |
US9330237B2 (en) | 2008-12-24 | 2016-05-03 | Medtronic Minimed, Inc. | Pattern recognition and filtering in a therapy management system |
US8198320B2 (en) | 2008-12-31 | 2012-06-12 | Taipei Medical University | Hypoglycemic activity of osthole |
JP5721637B2 (ja) | 2009-01-07 | 2015-05-20 | 海▲東▼ 黄 | ヒトグルコキナーゼ変異体コード遺伝子、そのコードされた酵素、組換えベクターおよび宿主、その医薬組成物、使用および疾病の予防と治療の方法 |
US20120053222A1 (en) | 2009-01-23 | 2012-03-01 | Mark Gorrell | Novel Metabolic Disease Therapy |
US20140363794A1 (en) | 2009-01-26 | 2014-12-11 | EosHealth, Inc. | Diabetic Patients Compliance and Outcomes by Publicizing that Increased Compliance Improves Blood Glucose Control and Outcomes |
BRPI1008849B8 (pt) | 2009-02-04 | 2021-06-22 | Sanofi Aventis Deutschland | dispositivo médico e método para controle glicêmico |
CA2750052C (en) | 2009-02-04 | 2017-08-22 | Sanofi-Aventis Deutschland Gmbh | Medical system and method for providing glycemic control based on glycemic response information |
EP2393419A4 (en) | 2009-02-04 | 2014-10-15 | Abbott Diabetes Care Inc | MULTIFUNCTIONAL ANALYTIC PROCESSING DEVICE AND METHOD THEREFOR |
AU2010210181B2 (en) | 2009-02-04 | 2015-01-22 | Sanofi-Aventis Deutschland Gmbh | Medical device and method for providing information for glycemic control |
AU2010210157B2 (en) | 2009-02-04 | 2014-08-28 | Sanofi-Aventis Deutschland Gmbh | Medical system and method for providing information for glycemic control |
AU2010217221A1 (en) | 2009-02-26 | 2011-08-25 | Dreamed Diabetes Ltd. | Method and system for automatic monitoring of diabetes related treatments |
WO2010111660A1 (en) * | 2009-03-27 | 2010-09-30 | Dexcom, Inc. | Methods and systems for promoting glucose management |
WO2010120736A1 (en) | 2009-04-14 | 2010-10-21 | Abbott Laboratories | High fiber nutritional emulsions for blood glucose control |
WO2010129375A1 (en) | 2009-04-28 | 2010-11-11 | Abbott Diabetes Care Inc. | Closed loop blood glucose control algorithm analysis |
WO2010135654A2 (en) | 2009-05-22 | 2010-11-25 | Abbott Diabetes Care Inc. | Safety features for integrated insulin delivery system |
WO2010135646A1 (en) | 2009-05-22 | 2010-11-25 | Abbott Diabetes Care Inc. | Usability features for integrated insulin delivery system |
US8398616B2 (en) | 2009-05-22 | 2013-03-19 | Abbott Diabetes Care Inc. | Safety layer for integrated insulin delivery system |
GB2471066A (en) | 2009-06-10 | 2010-12-22 | Dna Electronics Ltd | A glucagon pump controller |
US9687194B2 (en) | 2009-06-17 | 2017-06-27 | Medtronic Minimed, Inc. | Closed-loop glucose and/or insulin control system |
US9218453B2 (en) | 2009-06-29 | 2015-12-22 | Roche Diabetes Care, Inc. | Blood glucose management and interface systems and methods |
US20100331652A1 (en) | 2009-06-29 | 2010-12-30 | Roche Diagnostics Operations, Inc. | Modular diabetes management systems |
EP3973855A1 (en) | 2009-06-30 | 2022-03-30 | Lifescan, Inc. | Analyte testing methods and device for calculating basal insulin therapy |
WO2011002791A2 (en) | 2009-06-30 | 2011-01-06 | Lifescan Scotland Limited | Systems for diabetes management and methods |
CN102018766B (zh) | 2009-09-16 | 2013-03-06 | 博仲盛景医药技术(北京)有限公司 | 一种植物提取物、其提取方法和用途及含有这种提取物的组合物 |
US20110071464A1 (en) | 2009-09-23 | 2011-03-24 | Medtronic Minimed, Inc. | Semi-closed loop insulin delivery |
KR101632308B1 (ko) | 2009-09-23 | 2016-06-21 | 삼성전자주식회사 | 혈당 관리 정보를 제공하는 방법 및 장치 |
RU2559931C2 (ru) | 2009-09-29 | 2015-08-20 | Лайфскэн Скотлэнд Лимитед | Способ тестирования аналита и устройство для контроля для пациентов, страдающих сахарным диабетом |
AU2010302266A1 (en) * | 2009-09-30 | 2012-04-19 | Dreamed Diabetes Ltd. | Monitoring Device for Management of Insulin Delivery |
US20110098548A1 (en) | 2009-10-22 | 2011-04-28 | Abbott Diabetes Care Inc. | Methods for modeling insulin therapy requirements |
US20110098637A1 (en) * | 2009-10-27 | 2011-04-28 | Medtronic Minimed, Inc. | Method and System for Configuring an Insulin Infusion Device |
US20110115894A1 (en) | 2009-11-19 | 2011-05-19 | Daniel Rogers Burnett | Device and method for diagnosis and monitoring of neural, opthalmologic and retinal disorders |
US20110124996A1 (en) * | 2009-11-20 | 2011-05-26 | Roche Diagnostics Operations, Inc. | Diabetes health management systems and methods |
US8771251B2 (en) | 2009-12-17 | 2014-07-08 | Hospira, Inc. | Systems and methods for managing and delivering patient therapy through electronic drug delivery systems |
WO2011073788A2 (en) | 2009-12-18 | 2011-06-23 | Dr Reddy's Laboratories, Limited | Balaglitazone compositions and methods |
US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
DK2525863T3 (en) | 2010-01-20 | 2019-01-21 | Hoffmann La Roche | METHOD AND DEVICE FOR IMPROVING Glycemic Control |
WO2011094352A1 (en) | 2010-01-27 | 2011-08-04 | Baylor Research Institute | In-vivo non-viral gene delivery of human vascular endothelial growth factor following islet transplantation |
US8579879B2 (en) | 2010-02-19 | 2013-11-12 | Medtronic Minimed, Inc. | Closed-loop glucose control startup |
US20110213332A1 (en) | 2010-03-01 | 2011-09-01 | Koorosh Mozayeny | Medication delivery system |
US9089292B2 (en) | 2010-03-26 | 2015-07-28 | Medtronic Minimed, Inc. | Calibration of glucose monitoring sensor and/or insulin delivery system |
US9144586B2 (en) | 2010-04-07 | 2015-09-29 | Incube Labs, Llc | Method for treating glucose related disorders using stem cell-derived gastro-intestinal cells |
US20120197358A1 (en) | 2010-04-09 | 2012-08-02 | Prescott Marvin A | Light Therapy for Treating or Managing Diabetes and Metabolic Syndrome |
JP2011237408A (ja) | 2010-04-14 | 2011-11-24 | Arkray Inc | 生体情報測定装置、生体情報測定装置における照明方法、および生体情報測定方法 |
US9387279B2 (en) | 2010-05-05 | 2016-07-12 | The Governing Council Of The University Of Toronto | Implantable-glucose responsive insulin delivery device |
US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
US10561785B2 (en) | 2010-06-22 | 2020-02-18 | Medtronic Minimed, Inc. | Method and/or system for closed-loop control of glucose to a treatment range |
US8543354B2 (en) | 2010-06-23 | 2013-09-24 | Medtronic Minimed, Inc. | Glucose sensor signal stability analysis |
US20120003339A1 (en) | 2010-07-02 | 2012-01-05 | Minacapelli Pompeo | Compositions and methods for controlling blood glucose levels |
US20120006100A1 (en) | 2010-07-06 | 2012-01-12 | Medtronic Minimed, Inc. | Method and/or system for determining blood glucose reference sample times |
WO2012004773A1 (en) | 2010-07-09 | 2012-01-12 | Universite De Geneve | New uses of nogo-a inhibitors and related methods |
US8870807B2 (en) | 2010-07-19 | 2014-10-28 | Surag Mantri | Gastro-intestinal compression device |
CN103003819A (zh) | 2010-07-23 | 2013-03-27 | 霍夫曼-拉罗奇有限公司 | 考虑到身体活动对葡萄糖调节系统的影响的系统和方法 |
US8679170B2 (en) | 2010-07-23 | 2014-03-25 | Avacen, Inc. | Methods and apparatus for therapeutic application of thermal energy |
WO2012019746A1 (en) | 2010-08-10 | 2012-02-16 | Roche Diagnostics Gmbh | Method and system for improving glycemic control |
WO2012024270A1 (en) | 2010-08-17 | 2012-02-23 | Abbott Laboratories | Nutritional composition comprising cereal beta-glucan and salacia extract |
US8206340B2 (en) | 2010-08-18 | 2012-06-26 | Thuban, Inc. | Integrated glucose monitor and insulin injection pen with automatic emergency notification |
US20120058942A1 (en) | 2010-09-03 | 2012-03-08 | John Dupre | Methods for controlling blood-glucose levels in insulin-requiring subjects |
WO2012047800A1 (en) | 2010-10-06 | 2012-04-12 | Abbott Laboratories | Methods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend |
US8588687B2 (en) | 2010-10-15 | 2013-11-19 | Roche Diagnostics Operations, Inc. | Coexistence of multiple radios in a medical device |
TW201305098A (zh) | 2010-10-27 | 2013-02-01 | Prometic Biosciences Inc | 用於糖尿病的化合物和藥物組合物 |
US8919180B2 (en) | 2010-10-28 | 2014-12-30 | Medtronic Minimed, Inc. | Determination and application of glucose sensor reliability indicator and/or metric |
US8657746B2 (en) | 2010-10-28 | 2014-02-25 | Medtronic Minimed, Inc. | Glucose sensor signal purity analysis |
WO2012058694A2 (en) | 2010-10-31 | 2012-05-03 | Trustees Of Boston University | Blood glucose control system |
US8349612B2 (en) | 2010-11-15 | 2013-01-08 | Roche Diagnostics Operations, Inc. | Guided structured testing kit |
US20130231312A1 (en) | 2010-11-16 | 2013-09-05 | Shengkan Jin | Treatment of type ii diabetes and diabetes-associated diseases with safe chemical mitochondrial uncouplers |
CN102462736B (zh) | 2010-11-19 | 2015-07-15 | 北京唐安营养保健品有限公司 | 肉桂水提取物的制备方法 |
US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
US8329232B2 (en) | 2010-11-23 | 2012-12-11 | Beijing Tang-An Nutrition & Healthcare Products Co. Ltd. | Process for preparing water extract of cinnamon |
ES2396844B1 (es) | 2010-12-01 | 2014-01-27 | Universitat Politècnica De Catalunya | Sistema y método para la estimación simultánea y no invasiva de la glucosa en la sangre, nivel de glucocorticoides y presión arterial |
WO2012073987A1 (ja) | 2010-12-01 | 2012-06-07 | キッコーマン株式会社 | 大腸菌形質転換体、それを用いたフラビン結合型グルコースデヒドロゲナーゼの製造方法、および、変異型フラビン結合型グルコースデヒドロゲナーゼ |
JP5969392B2 (ja) | 2010-12-02 | 2016-08-17 | キッコーマン株式会社 | フラビン結合型グルコースデヒドロゲナーゼ、フラビン結合型グルコースデヒドロゲナーゼの製造方法およびそれに用いる酵母形質転換体 |
CA2821807A1 (en) | 2010-12-21 | 2012-06-28 | Nestec S.A. | Methods and compositions suitable for managing blood glucose in animals |
US20120173151A1 (en) | 2010-12-29 | 2012-07-05 | Roche Diagnostics Operations, Inc. | Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels |
WO2012097064A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for controlling blood glucose |
SG191772A1 (en) | 2011-01-31 | 2013-08-30 | Cadila Healthcare Ltd | Treatment for lipodystrophy |
WO2012122520A1 (en) | 2011-03-10 | 2012-09-13 | Abbott Diabetes Care Inc. | Multi-function analyte monitor device and methods of use |
WO2012123765A1 (en) | 2011-03-17 | 2012-09-20 | University Of Newcastle Upon Tyne | System for the self-monitoring and regulation of blood glucose |
MX339374B (es) | 2011-04-29 | 2016-05-13 | Inst De Investigación En Química Aplic S A De C V | Cocristales ionicos con base en metformina. |
US9011510B2 (en) | 2011-05-09 | 2015-04-21 | The Invention Science Fund I, Llc | Method, device and system for modulating an activity of brown adipose tissue in a vertebrate subject |
US8766803B2 (en) | 2011-05-13 | 2014-07-01 | Roche Diagnostics Operations, Inc. | Dynamic data collection |
US8755938B2 (en) | 2011-05-13 | 2014-06-17 | Roche Diagnostics Operations, Inc. | Systems and methods for handling unacceptable values in structured collection protocols |
WO2012170531A1 (en) | 2011-06-07 | 2012-12-13 | Wisconsin Alumni Research Foundation | Hepatocyte based insulin gene therapy for diabetes |
US20130022592A1 (en) | 2011-06-17 | 2013-01-24 | Daniel Edward Vaughn | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme |
EP2723229B1 (en) | 2011-06-23 | 2018-09-26 | University Of Virginia Patent Foundation | Unified platform for monitoring and control of blood glucose levels in diabetic patients |
AU2012286753A1 (en) | 2011-07-26 | 2014-02-06 | Glysens Incorporated | Tissue implantable sensor with hermetically sealed housing |
US8667293B2 (en) | 2011-08-11 | 2014-03-04 | Roche Diagnostics Operations, Inc. | Cryptographic data distribution and revocation for handheld medical devices |
GB2493712B (en) | 2011-08-12 | 2014-07-02 | Gene Onyx Ltd | Insulin pump |
WO2013024160A2 (en) | 2011-08-18 | 2013-02-21 | Novo Nordisk A/S | Drug delivery device with means for handling data |
WO2013040712A1 (en) | 2011-09-20 | 2013-03-28 | Afexa Life Sciences Inc. | Composition comprising ku ding cha and ginseng for managing blood glucose levels |
FI3689235T3 (fi) | 2011-09-28 | 2024-06-19 | Abbott Diabetes Care Inc | Menetelmät analyytin tarkkailun hallintaan ja analyytin mittausdatan hallintaan sekä näihin liittyvät tuotteet |
US20130085682A1 (en) | 2011-10-04 | 2013-04-04 | Roche Diagnostics Operations, Inc. | Memory card usage with blood glucose devices |
EP2763722B1 (en) | 2011-10-07 | 2016-08-10 | Novo Nordisk A/S | System for determining position of element based on three-axial magnetic sensors |
US20130144283A1 (en) | 2011-12-02 | 2013-06-06 | Medtronic Ardian Luxembourg S.A.R.L. | Treatment of polycystic ovary syndrome using renal neuromodulation and associated systems and methods |
CA2858566A1 (en) | 2011-12-09 | 2013-06-13 | Joel R. Ehrenkranz | System and methods for monitoring food consumption |
TW201333870A (zh) | 2011-12-21 | 2013-08-16 | 艾登工具股份有限公司 | 決定病人胰島素療法的系統及方法 |
WO2013101749A1 (en) | 2011-12-29 | 2013-07-04 | Latitude Pharmaceuticals, Inc. | Stabilized glucagon nanoemulsions |
US20130172688A1 (en) | 2011-12-29 | 2013-07-04 | Roche Diagnostics Operations, Inc. | Diabetes management application for mobile phone |
US9136939B2 (en) * | 2011-12-29 | 2015-09-15 | Roche Diabetes Care, Inc. | Graphical user interface pertaining to a bolus calculator residing on a handheld diabetes management device |
WO2013108262A1 (en) | 2012-01-18 | 2013-07-25 | Zota Health Care Ltd | Synergistic combination for the treatment of diabetic neuropathy |
US10694983B2 (en) | 2012-01-19 | 2020-06-30 | Medtronic Minimed, Inc. | Method and/or system for assessing a patient's glycemic response |
EP2805275A1 (en) | 2012-01-20 | 2014-11-26 | Mueller-Wolf, Martin | "indima apparatus" system, method and computer program product for individualized and collaborative health care |
KR101166907B1 (ko) | 2012-02-08 | 2012-07-19 | 최병철 | 혈당조절 및 생리활성 작용을 하는 서목태(쥐눈이콩) 엑기스와 그 제조방법 |
US20150031053A1 (en) | 2012-02-10 | 2015-01-29 | Alere Switzerland Gmbh | Assay and method for determining insulin-resistance |
ES2421956B1 (es) | 2012-03-02 | 2014-09-29 | Moehs Ibérica S.L. | Nueva forma cristalina de sulfato de sitagliptina |
US9080939B2 (en) | 2012-03-06 | 2015-07-14 | National Central University | Method of measuring glycosylated protein proportion by AC impedance method |
CN104254367A (zh) | 2012-03-07 | 2014-12-31 | 美敦力阿迪安卢森堡有限公司 | 肾神经的选择性调制 |
AU2013230781B2 (en) | 2012-03-08 | 2015-12-03 | Medtronic Af Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
US20140337041A1 (en) | 2012-03-30 | 2014-11-13 | Joseph Madden | Mobile Application for Defining, Sharing and Rewarding Compliance with a Blood Glucose Level Monitoring Regimen |
US20130281796A1 (en) | 2012-04-20 | 2013-10-24 | Broadmaster Biotech Corp. | Biosensor with exercise amount measuring function and remote medical system thereof |
MX350999B (es) | 2012-05-16 | 2017-09-27 | Melaleuca Inc Star | Composiciones de suplementos dieteticos. |
US20130317316A1 (en) | 2012-05-25 | 2013-11-28 | City Of Hope | Carbohydrate modeling methods, systems, and devices |
US20150174209A1 (en) | 2012-05-25 | 2015-06-25 | Amylin Pharmaceuticals. Llc | Insulin-pramlintide compositions and methods for making and using them |
US9150482B2 (en) | 2012-06-06 | 2015-10-06 | Development Center For Biotechnology | GLP-1 potentiators from hedychium coronarium and their applications |
US9254099B2 (en) | 2013-05-23 | 2016-02-09 | Medibotics Llc | Smart watch and food-imaging member for monitoring food consumption |
US9536449B2 (en) | 2013-05-23 | 2017-01-03 | Medibotics Llc | Smart watch and food utensil for monitoring food consumption |
US9861744B2 (en) | 2012-06-25 | 2018-01-09 | International Business Machines Corporation | Managing blood glucose levels |
US20140012510A1 (en) | 2012-07-09 | 2014-01-09 | Dexcom, Inc | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
US8492426B1 (en) | 2012-07-12 | 2013-07-23 | Anis Ahmad | Use of carvedilol for treatment of diabetes mellitus |
US20140024907A1 (en) | 2012-07-19 | 2014-01-23 | Lifescan, Inc. | Method and system to indicate hyperglycemia or hypoglycemia for people with diabetes |
WO2014024201A1 (en) | 2012-08-06 | 2014-02-13 | Ramchandran T S | Regulate and manage blood glucose levels of a subject by promoting cell metabolism with the application of low frequency (20 khz to 70 khz ) airborne ultrasound waves and a machine to produce the airborne ultrasound waves therefor |
AR092077A1 (es) | 2012-08-10 | 2015-03-18 | Sanofi Aventis Deutschland | Sistema medico |
WO2014028607A1 (en) | 2012-08-14 | 2014-02-20 | Abbott Laboratories | Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics |
US9504411B2 (en) | 2012-08-28 | 2016-11-29 | Roche Diabetes Care, Inc. | Diabetes manager for glucose testing and continuous glucose monitoring |
US9662445B2 (en) | 2012-08-30 | 2017-05-30 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
US9278200B2 (en) | 2012-09-19 | 2016-03-08 | Mackay Memorial Hospital | Flow control device, system and method for controlling the flow of body fluid |
ITTV20120186A1 (it) | 2012-09-28 | 2014-03-29 | Alpinestars Res Srl | Calzatura sportiva |
EP2727587A1 (en) | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
PE20151518A1 (es) | 2012-11-13 | 2015-11-25 | Gordagen Pharmaceuticals Pty Ltd | Administracion transmucosa de tocotrienol |
CN104780931B (zh) | 2012-12-17 | 2018-05-18 | 星系有限公司 | Bt脂肽作为用于肥胖和相关疾病的治疗剂的用途 |
US9351670B2 (en) | 2012-12-31 | 2016-05-31 | Abbott Diabetes Care Inc. | Glycemic risk determination based on variability of glucose levels |
US9192509B2 (en) | 2013-03-11 | 2015-11-24 | Avacen, Inc. | Methods and apparatus for therapeutic application of thermal energy including blood viscosity adjustment |
US20140296943A1 (en) | 2013-03-14 | 2014-10-02 | Biological Illumination, Llc | Method for controlling blood glucose levels and digestion cycles |
US9795737B2 (en) | 2013-03-15 | 2017-10-24 | Animas Corporation | Method and system for closed-loop control of an artificial pancreas |
EP2967506B1 (en) | 2013-03-15 | 2020-04-29 | Becton, Dickinson and Company | Smart adapter for infusion devices |
CN105377118B (zh) | 2013-03-15 | 2019-09-17 | 雅培糖尿病护理公司 | 与分析物监视设备相关联的设备、系统和方法以及包含其的设备 |
WO2014149781A1 (en) | 2013-03-15 | 2014-09-25 | Cercacor Laboratories, Inc. | Cloud-based physiological monitoring system |
US9619849B2 (en) * | 2013-03-26 | 2017-04-11 | Eric Lee Rock | Healthcare delivery system and method |
WO2014162549A1 (ja) | 2013-04-04 | 2014-10-09 | テルモ株式会社 | 血糖管理システム |
US20140303466A1 (en) | 2013-04-06 | 2014-10-09 | Applivate, LLC | Computer-Based Monitoring of Blood Glucose Levels |
US9237866B2 (en) | 2013-04-29 | 2016-01-19 | Birch Narrows Development, LLC | Blood glucose management |
US20160089500A1 (en) | 2013-05-21 | 2016-03-31 | Novo Nordisk A/S | Drug Delivery Device with Means for Disabling Activation of Expelling Mechanism |
EP3000065A4 (en) | 2013-05-23 | 2017-01-18 | Iphenotype LLC | Phenotypic integrated social search database and method |
US9529385B2 (en) | 2013-05-23 | 2016-12-27 | Medibotics Llc | Smart watch and human-to-computer interface for monitoring food consumption |
US9056049B2 (en) | 2013-05-30 | 2015-06-16 | Chin Yuan Huang | Micro-particle comprising a protein extract from sweet potato for extending satiety and controlling blood glucose and lipid levels |
CN103432572B (zh) | 2013-06-21 | 2018-09-18 | 四川大学华西医院 | 一种恒河猴糖尿病肾病模型的制备方法 |
US9482635B2 (en) | 2013-06-25 | 2016-11-01 | Animas Corporation | Glucose-measurement systems and methods presenting icons |
US20160038077A1 (en) | 2013-06-27 | 2016-02-11 | Inspark Technologies, Inc. | Systems, Devices, and/or Methods for Identifying Time Periods of Insufficient Blood Glucose Testing |
US9486580B2 (en) * | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9878097B2 (en) * | 2015-04-29 | 2018-01-30 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
-
2014
- 2014-10-09 US US14/511,060 patent/US9486580B2/en active Active
-
2015
- 2015-01-13 AU AU2015211352A patent/AU2015211352B2/en active Active
- 2015-01-13 EP EP15743578.5A patent/EP3046599B1/en active Active
- 2015-01-13 CA CA2926761A patent/CA2926761C/en active Active
- 2015-01-13 EP EP21186597.7A patent/EP3926638A1/en active Pending
- 2015-01-13 WO PCT/US2015/011086 patent/WO2015116371A1/en active Application Filing
- 2015-01-13 JP JP2016567332A patent/JP6602784B2/ja active Active
-
2016
- 2016-07-25 IL IL246936A patent/IL246936A/en active IP Right Grant
- 2016-09-06 HK HK16110587.0A patent/HK1222357A1/zh unknown
- 2016-09-22 US US15/272,972 patent/US9604002B2/en active Active
- 2016-11-02 US US15/342,102 patent/US9710611B2/en active Active
-
2017
- 2017-06-14 US US15/623,065 patent/US9892235B2/en active Active
- 2017-12-28 US US15/856,363 patent/US11311213B2/en active Active
-
2019
- 2019-07-08 JP JP2019126913A patent/JP6882383B2/ja active Active
-
2022
- 2022-04-18 US US17/659,652 patent/US11490837B2/en active Active
- 2022-10-28 US US18/050,591 patent/US11857314B2/en active Active
-
2023
- 2023-10-09 US US18/483,487 patent/US12127831B2/en active Active
-
2024
- 2024-06-17 US US18/745,055 patent/US20240335145A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11857314B2 (en) | 2024-01-02 |
US20220248989A1 (en) | 2022-08-11 |
HK1222357A1 (zh) | 2017-06-30 |
EP3046599A4 (en) | 2017-08-02 |
IL246936A (en) | 2017-02-28 |
AU2015211352A1 (en) | 2016-05-05 |
IL246936A0 (en) | 2016-11-02 |
EP3926638A1 (en) | 2021-12-22 |
US9710611B2 (en) | 2017-07-18 |
US20230087860A1 (en) | 2023-03-23 |
US9892235B2 (en) | 2018-02-13 |
AU2015211352B2 (en) | 2019-04-18 |
US12127831B2 (en) | 2024-10-29 |
US9486580B2 (en) | 2016-11-08 |
US11311213B2 (en) | 2022-04-26 |
US20170007761A1 (en) | 2017-01-12 |
JP2019213866A (ja) | 2019-12-19 |
WO2015116371A1 (en) | 2015-08-06 |
US20180122505A1 (en) | 2018-05-03 |
CA2926761C (en) | 2023-02-21 |
EP3046599A1 (en) | 2016-07-27 |
US11490837B2 (en) | 2022-11-08 |
US20150217053A1 (en) | 2015-08-06 |
JP6602784B2 (ja) | 2019-11-06 |
US9604002B2 (en) | 2017-03-28 |
US20170281098A1 (en) | 2017-10-05 |
US20240335145A1 (en) | 2024-10-10 |
CA2926761A1 (en) | 2015-08-06 |
JP2017505695A (ja) | 2017-02-23 |
US20170076067A1 (en) | 2017-03-16 |
EP3046599B1 (en) | 2021-07-21 |
US20240041357A1 (en) | 2024-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6882383B2 (ja) | インスリン管理 | |
US11621074B2 (en) | Insulin management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190805 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190805 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210405 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210506 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6882383 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |